{
    "paper_id": "5aaef5ab4830bb92870de846135b632476b135eb",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [
        {
            "text": "Hematopoietic (bone marrow) failure with pancytopenia (bi-or tricytopenia) of the peripheral blood. Characteristics: hypocellular bone marrow with fatty substitution; no bone marrow stromal cell defects; no malignant cells.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Incidence worldwide: 2-6 cases per 1,000,000 population/year; much higher in China, the Far East, and South East Asia. Age distribution: two peaks, around 20 years and 65 years. Class: Class: Sy: Sy: Dg: Dg: 1. Aplastic anemia should always be treated in a hematological center. 2. Patients under 55 years of age with HLA-identical siblings or relatives should be evaluated for matched related allogeneic bone marrow or blood stem cell transplantation. 3. In other patients, immunosuppression is carried out in the framework of clinical trials. Dd: Dd: Co: Co: Th: Th: . Aplastic Anemia Relapse \u2022 After matched related allogeneic transplantation: 15-20% \u2022 After immunosuppressive medication (CyA + ATG containing): 30-50% Bacigalupo A, Bruno B, Saracco P et al. Antilymphocyte globulin, cyclosporin, and granulocyte colonystimulating factor for severe aplastic anemia: an update of the GITMO/EBMT Working Party. Blood 2000;95:1931-34 Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000;110:41-53 Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647-56 Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007;136:549-64 Geroges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol 2002;75:141-6 Kojima S, Hibi S, Kosaka Y et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporin, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-54 Marsh JCW, Ball SE, Darbyshire P et al. British Committee for Standards in Hematology (BCSH). Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 2003;123:782-90 Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413-24 Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002;75:129-40",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Destruction / suppression of hematopoietic stem cells or progenitor cells caused by various factors is of central importance: \u2022 Activation of the immune system with primary or secondary (immunologically induced) bone marrow aplasia with activated cytotoxic T-cells, which cause destruction of CD34-positive progenitor cells via: -Direct T-cell-mediated cytotoxicity -Production of IFN\u03b3 and TNF\u03b2 -Induction of FAS receptor and antigen \u2192 apoptosis induction \u2022 Direct DNA damage (e.g., irradiation) \u2022 Cellular membrane damage and interference with the cellular metabolism (e.g., viral infection) \u2022 Drug-induced: direct toxicity or hapten-mediated autoimmune reaction \u2022 Secondary clonal expansion of hematopoiesis \u2022 NK cells \u2193 (as with other autoimmune diseases)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pathophysiological Model"
        },
        {
            "text": "\u2022 Fanconi's anemia: chromosomal instability based on multiple genetic defects (Fanconi anemia genes FANC A-L). Characteristics are: progressive bone marrow aplasia, increased incidence of malignancy, and abnormalities in skin, musculature, skeletal system, and urogenital system. In > 80% of cases, manifestation is during infancy. \u2022 Increased incidence of aplastic anemia in the presence of HLA A2, DR2, DR4, and DPw3. \u2022 PNH association (7 Chap. 6.4 ",
            "cite_spans": [
                {
                    "start": 438,
                    "end": 450,
                    "text": "(7 Chap. 6.4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Genetic Factors"
        },
        {
            "text": "\u2022 Antibiotics (particularly sulfonamides, chloramphenicol), antimalarial drugs \u2022 Thyreostatics, antidiabetics \u2022 Antirheumatics, NSAIDs (e.g., phenylbutazone, gold) \u2022 Diuretics (furosemide), ticlopidine, nifedipine \u2022 Antiepileptics (e.g., carbamazepine, phenytoin) \u2022 Cytotoxic compounds (e.g., busulfan)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Drugs (in 25% of Cases)"
        },
        {
            "text": "\u2022 Aromatic solvents (e.g., benzene) \u2022 Insecticides (lindane, DDT, etc.) ",
            "cite_spans": [
                {
                    "start": 61,
                    "end": 71,
                    "text": "DDT, etc.)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Chemical Agents"
        },
        {
            "text": "\u2022 Parvovirus B19 (isolated erythropoietic aplasia, \"pure red cell anemia\") \u2022 Hepatitis (non-A-B-C-G hepatitis, poor prognosis, mostly young men) \u2022 EBV (infectious mononucleosis, rare) \u2022 HIV ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Viral / Postinfectious (5% of Cases)"
        },
        {
            "text": "\u2022 Complete blood count: bi-or trilineage cytopenia, generally without pathological morphology, increased granulation, neutropenia, monocytopenia, and eosinopenia; reticulocytes \u2193; in cases of thrombocytopenia: small platelets \u2022 Ferritin, haptoglobin, Coombs' test, blood group, coagulation parameters \u2022 ESR, total protein, electrophoresis, immunoglobulins, immunofixation, cold agglutinins, rheumatoid factor, ANA \u2022 PNH exclusion (Ham's test, sugar water test, GPI-linked proteins, CD55, CD59) \u2022 Vitamin B12, folic acid (exclusion of megaloblastic anemia) \u2022 Liver function (exclude past history of hepatitis) \u2022 Serology (EBV, CMV, HAV, HBV, HCV, HIV, HSV, parvovirus B19)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "\u2022 Hypocellular (cellularity < 25%) with predominance of fat cells \u2022 Lymphocytes, macrophages, and plasma cells present \u2022 CD34-positive progenitor cells \u2193; in bone marrow cultures, reduced colony formation (CFU-GM, colony-forming units -granulocytes / macrophages) and LTCIC (long-term culture-initiating cells). Improved growth pattern in T-cell-depleted cultures (\u2192 T-cell-mediated reaction?)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bone Marrow (Aspiration, Histology, Immunohistochemistry, Iron Stain, Culture)"
        },
        {
            "text": "\u2022 Chest x-ray, abdominal sonography \u2022 HLA typing (in cases of potential transplantation) \u2022 Cytogenetics, chromosome analysis (exclusion of MDS, Fanconi's anemia) \u2022 Increased serum levels of hematopoietic growth factors: G-CSF (granulocyte colony-stimulating factor), TPO (thrombopoietin), M-CSF, and erythropoietin; SCF (stem cell factor) not increased",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Further Diagnostic Procedures"
        },
        {
            "text": "\u2022 Myelodysplasia with hypoplastic bone marrow (7 Chap. 7 .2) \u2022 Primary Myelofibrosis (PM) (7 Chap. 7.3.4) \u2022 Vitamin B12 deficiency, folic acid deficiency (7 Chap. 6.4.2) \u2022 Paroxysmal nocturnal hemoglobinuria (PNH) (7 Chap. 6.4 .3) \u2022 Leukemias, lymphomas, solid tumors with bone marrow infiltration",
            "cite_spans": [
                {
                    "start": 46,
                    "end": 56,
                    "text": "(7 Chap. 7",
                    "ref_id": null
                },
                {
                    "start": 90,
                    "end": 105,
                    "text": "(7 Chap. 7.3.4)",
                    "ref_id": null
                },
                {
                    "start": 154,
                    "end": 169,
                    "text": "(7 Chap. 6.4.2)",
                    "ref_id": null
                },
                {
                    "start": 214,
                    "end": 226,
                    "text": "(7 Chap. 6.4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Further Diagnostic Procedures"
        },
        {
            "text": "\u2022 Development of PNH in 7% of cases (7 Chap. 6.4 .3) \u2022 Transformation into MDS or acute leukemia in 5-12% of cases (7 Chaps. 7.1.1, 7.1.2, 7.2) Indications for Treatment ",
            "cite_spans": [
                {
                    "start": 36,
                    "end": 48,
                    "text": "(7 Chap. 6.4",
                    "ref_id": null
                },
                {
                    "start": 115,
                    "end": 131,
                    "text": "(7 Chaps. 7.1.1,",
                    "ref_id": null
                },
                {
                    "start": 132,
                    "end": 138,
                    "text": "7.1.2,",
                    "ref_id": null
                },
                {
                    "start": 139,
                    "end": 143,
                    "text": "7.2)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Further Diagnostic Procedures"
        },
        {
            "text": "Hematology and Hemostasis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Part"
        },
        {
            "text": "\u2022 Infection prophylaxis, antibiotics, amphotericin B prophylaxis \u2022 Oral hygiene \u2022 Prophylaxis / therapy of hemosiderosis (desferrioxamine mesylate) \u2022 Granulocyte transfusions (7 Chap. 5.4) \u2022 Suppress menses, avoid platelet aggregation inhibitors \u2022 Blood products (CMV negative, irradiated); erythrocyte transfusions according to symptoms, platelet transfusions for counts below 5,000-10,000/\u00b5l \u2022 Growth factors: granulocyte colony-stimulating factor (G-CSF), erythropoietic factors ATTENTION: use blood products as sparingly as possible until decision on BMT / PBSCT is made (danger of alloimmunization). Do not use blood products from relatives.",
            "cite_spans": [
                {
                    "start": 175,
                    "end": 188,
                    "text": "(7 Chap. 5.4)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Supportive Measures"
        },
        {
            "text": "Transplantation Types (7 Chaps. 5.2, 5. 3) \u2022 In patients under 55 years of age, allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical related (family) donors in conjunction with fludarabine / cyclophosphamide-containing protocols \u2022 Matched unrelated donor (MUD) transplantation recommended only in patients under 15 years of age",
            "cite_spans": [
                {
                    "start": 22,
                    "end": 36,
                    "text": "(7 Chaps. 5.2,",
                    "ref_id": null
                },
                {
                    "start": 37,
                    "end": 39,
                    "text": "5.",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 43,
                    "end": 44,
                    "text": "\u2022",
                    "ref_id": null
                },
                {
                    "start": 131,
                    "end": 137,
                    "text": "(HSCT)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Supportive Measures"
        },
        {
            "text": "\u2022 Most common form: drug-induced toxic suppression of granulopoiesis or direct neutrophilic damage (\"delayed onset neutropenia, \" e.g., after radio-or chemotherapy), usually with simultaneous thrombocytopenia (7 Chap. 6 .3) \u2022 Drug-induced allergic reactions with destruction of neutrophils, often caused by metabolites \u2022 Usually, rapid granulocyte decrease within 1 week after exposure; in case of re-exposure, within hours. Destruction of mature granulocytes (\"abrupt onset neutropenia\"), acute onset with fever and chills (DD: infection). Causative agent: e.g. phenylbutazone \u2022 In rare cases, slow decrease, between 1 and 12 months after the beginning of treatment, due to destruction of hematopoietic progenitor cells. Causative agent: e.g., clozapine, in patients with HLA phenotype B38 and alleles DR4 and DQw3",
            "cite_spans": [
                {
                    "start": 209,
                    "end": 219,
                    "text": "(7 Chap. 6",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Drug-induced Forms"
        },
        {
            "text": "\u2022 Autoimmune diseases: T-cell-mediated inhibition of granulopoiesis (Felty's syndrome, rheumatoid arthritis) or as a result of clonal T-cell expansion in patients with T-\u03b3-lymphoproliferative disease (\"T-\u03b3-disease\") \u2022 Complement activation (e.g., with hemodialysis, sepsis): expression of adhesion molecules on the surface of neutrophils \u2192 neutrophilic aggregation, capillary occlusion (esp. pulmonary capillaries) \u2022 Pseudoneutropenia (\"shift neutropenia\"): neutrophilic redistribution (shift) from the peripheral blood into the tissues, e.g., with infections",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Other Forms"
        },
        {
            "text": "\u2022 Congenital dysgenesis with familial pancytopenia \u2022 Reticular dysgenesis with congenital aleukocytosis: agranulocytosis + lymphoid hypoplasia + thymic aplasia; unknown etiology \u2022 Periodic neutropenia: stem cell regulation defect; neutropenic phases in 10-to 35-day intervals, compensatory monocytosis; autosomal dominant inheritance \u2022 Kostmann's syndrome: severe agranulocytosis in children (abnormal differentiation in the promyelocytic stage), reversible by administration of G-CSF (ATTENTION: possibly higher risk of MDS / AML development); autosomal dominant or recessive inheritance \u2022 X-linked agammaglobulinemia \u2022 Schwachman-Diamond-Oski syndrome: neutropenia + pancreatic insufficiency + metaphyseal dysplasia; unknown etiology; autosomal recessive inheritance \u2022 Neutropenia with bi-/ tetraploid leukocytes: abnormal phagocytosis and chemotaxis as well as bi-and tetraploid granulocytes \u2022 Ch\u00e9diak-Higashi syndrome: albinism + neurological disorders + leukocytic granulation abnormalities; unknown etiology \u2022 Dyskeratosis congenita: neutropenia, skin abnormalities; X-linked inheritance \u2022 Lazy leukocyte syndrome: chemotaxis defect (actin defect); unknown etiology",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Neutropenia Caused by Congenital Granulopoietic Disorders"
        },
        {
            "text": "\u2022 Cytostatic treatment, immunosuppressives, azidothymidine (AZT), benzenes, ionizing radiation \u2022 Idiosyncratic drug reactions (individual sensitivity) in 66% of cases: antibiotics (penicillin, chloramphenicol, cephalosporins, sulfonamides) , sulfasalazine, nonsteroidal antirheumatics (ibuprofen, indomethacin, phenylbutazone), phenothiazine, thyreostatics, quinidine, procainamide, propafenone, ticlopidine, antihistamines, anticonvulsives, nifedipine, levamisole, tamoxifen, allopurinol, tranquilizers, neuroleptics (clozapine), gold, captopril + interferon ",
            "cite_spans": [
                {
                    "start": 180,
                    "end": 239,
                    "text": "(penicillin, chloramphenicol, cephalosporins, sulfonamides)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Neutropenia Caused by Acquired Disorders of Granulopoiesis"
        },
        {
            "text": "\u2022 Bone marrow aspiration, biopsy and culture (CFU)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "\u2022 Abdominal sonography (spleen), chest x-ray (exclusion of infection)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Imaging"
        },
        {
            "text": "\u2022 Leukemia (7 Chaps. 7.1.1, 7.1.2) \u2022 Myelodysplasia (7 Chap. 7.2) \u2022 Primary Myelofibrosis (7 Chap. 7.3.4) \u2022 Aplastic anemia (7 Chap. 6.1) \u2022 Susceptibility to infections, fever (7 Chap. 4 .2) \u2022 Mucositis, gastroenteritis (\"neutropenic enterocolitis\")",
            "cite_spans": [
                {
                    "start": 11,
                    "end": 27,
                    "text": "(7 Chaps. 7.1.1,",
                    "ref_id": null
                },
                {
                    "start": 28,
                    "end": 34,
                    "text": "7.1.2)",
                    "ref_id": null
                },
                {
                    "start": 52,
                    "end": 65,
                    "text": "(7 Chap. 7.2)",
                    "ref_id": null
                },
                {
                    "start": 90,
                    "end": 105,
                    "text": "(7 Chap. 7.3.4)",
                    "ref_id": null
                },
                {
                    "start": 124,
                    "end": 137,
                    "text": "(7 Chap. 6.1)",
                    "ref_id": null
                },
                {
                    "start": 176,
                    "end": 186,
                    "text": "(7 Chap. 4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Imaging"
        },
        {
            "text": "\u2022 Hygiene, anti-infectious environment, isolation \u2022 Mucositis prophylaxis \u2022 Selective intestinal decontamination \u2022 Oral antimycosis (e.g., fluconazole 200 mg/day p.o.) \u2022 Signs of infection: blood cultures, urine and stool cultures, swabs, immediate start of empirical antibiotic treatment (7 Chap. 4 .2) \u2022 With severe infections: granulocyte transfusion (7 Chap. 5.4) ",
            "cite_spans": [
                {
                    "start": 289,
                    "end": 299,
                    "text": "(7 Chap. 4",
                    "ref_id": null
                },
                {
                    "start": 354,
                    "end": 367,
                    "text": "(7 Chap. 5.4)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Supportive Therapy"
        },
        {
            "text": "\u2022 Discontinue all drugs administered within 4 weeks of onset of symptoms \u2022 G-CSF (filgrastim, lenograstim) 5-10 \u00b5g/kg daily s.c.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of Acute Agranulocytosis"
        },
        {
            "text": "Treatment according to the assumed pathogenic causes, e.g.: \u2022 In patients with clinically relevant recurrent infections, G-CSF may be used as long-term treatment \u2022 Use of other hematopoietic growth factors in clinical studies: GM-CSF, IL-3, stem cell factor (SCF) \u2022 In cases of autoimmune neutropenia:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of Chronic Neutropenia"
        },
        {
            "text": "-Prednisolone 2 mg/kg daily p.o. (maximum 4 weeks) -Cyclosporin A (serum level target: 300-600 ng/ml): initial treatment over at least 4 weeks; if successful, continue for at least 3 months -Azathioprine 2-4 mg/kg daily \u2022 With hypersplenism: consider splenectomy (only after pneumococcus vaccination) \u2022 In cases of congenital neutropenia: consider allogeneic transplantation (7 Chap. 5 Web: Web:",
            "cite_spans": [
                {
                    "start": 375,
                    "end": 385,
                    "text": "(7 Chap. 5",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Treatment of Chronic Neutropenia"
        },
        {
            "text": ". Neutropenia and Agranulocytosis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of Chronic Neutropenia"
        },
        {
            "text": "Decreased platelet count (< 150,000/\u00b5l), most common cause of hemorrhagic diatheses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hematology and Hemostasis Part"
        },
        {
            "text": "\u2022 Thrombopoiesis: megakaryoblasts \u2192 megakaryocytes \u2192 platelets; regulated by thrombopoietin and other cytokines (e.g., IL-3, IL-6, IL-11) \u2022 Directly after being released by the bone marrow, approximately one third of platelets are reversibly stored in the spleen (\"pool\") \u2022 Two thirds of platelets circulate in the blood, life span 7-10 days, biological half-life 3-4 days;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Platelet Kinetics"
        },
        {
            "text": "15% of these platelets are spent daily to maintain hemostasis ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Platelet Kinetics"
        },
        {
            "text": "Splenomegaly (portal hypertension, splenic infiltration with hematological neoplasia).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Increased Splenic Platelet Sequestration (Hypersplenism)"
        },
        {
            "text": "\u2022 Heart valve and vascular prostheses \u2022 Extracorporeal circulation (surface activation) \u2022 Immune thrombocytopenia (ITP) (7 Chap. 6.3.1) \u2022 Microangiopathic disorders: hemolytic-uremic syndrome (HUS) , thrombotic-thrombocytopenic purpura (TTP) (7 Chap. 6.3 .3) \u2022 Disseminated intravascular coagulation (DIC) (7 Chap. 6.5.5) \u2022 Disturbances in platelet and coagulation factor interaction: von Willebrand's disease type IIb, heparin-induced thrombocytopenia (HIT) (7 Chap. 6.3 ",
            "cite_spans": [
                {
                    "start": 120,
                    "end": 135,
                    "text": "(7 Chap. 6.3.1)",
                    "ref_id": null
                },
                {
                    "start": 242,
                    "end": 254,
                    "text": "(7 Chap. 6.3",
                    "ref_id": null
                },
                {
                    "start": 306,
                    "end": 321,
                    "text": "(7 Chap. 6.5.5)",
                    "ref_id": null
                },
                {
                    "start": 459,
                    "end": 471,
                    "text": "(7 Chap. 6.3",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Accelerated Peripheral Platelet Turnover"
        },
        {
            "text": "Bone marrow aspiration and biopsy: megakaryocytes \u2193 in case of dysfunctional thrombopoiesis, megakaryocytes normal or \u2191 in cases of peripheral platelet loss. ATTENTION: if platelet count < 20,000/\u00b5l: risk of hemorrhage \u2192 iliac crest biopsy (no sternal puncture), apply careful pressure Imaging Chest x-ray (lymphomas, infections), abdominal sonography (lymphomas, spleen) NOTE: if plasmatic coagulation and blood vessels are normal, there is only a low risk of hemorrhage with a platelet count of > 10,000-20,000/\u00b5l. \"Pseudothrombocytopenia\": formation of platelet aggregates in EDTA blood: 0.1-2% of blood samples; cause: autoagglutinating IgG antibodies \u2192 In vitro platelet aggregation in the presence of the anticoagulant agent EDTA \u2192 False low count by automatic platelet counter \u2192 Repeat platelet count with citrated or heparinized blood \u2022 Therapeutic: at signs of bleeding or acute hemorrhage (e.g., petechiae, hemorrhage of mucous membranes or epistaxis) with proven thrombocytopenia or thrombocyte dysfunction. \u2022 Prophylactic: platelet count < 10,000-20,000/\u00b5l. With concomitant diseases (especially acute leukemia, fever, sepsis, splenomegaly) risk of hemorrhage with higher platelet counts (20,000-30,000/\u00b5l). With invasive interventions (e.g., catheter installation, punctures) the platelet count target is > 40,000-60,000/\u00b5l. To avoid alloimmunization, transfusions should be avoided in patients scheduled for allogeneic hematopoietic stem cell transplantation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Acquired thrombocytopenia, platelet count < 150,000/\u00b5l.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of the Underlying Disease"
        },
        {
            "text": "Classic definition: ITP = idiopathic thrombocytopenic purpura. Diagnosis by exclusion; acquired thrombocytopenia of unknown etiology with normal to increased megakaryocyte count in the bone marrow.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of the Underlying Disease"
        },
        {
            "text": "Alternative definition: ITP = immune thrombocytopenic purpura. Acquired thrombocytopenia caused by antithrombocytic antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment of the Underlying Disease"
        },
        {
            "text": "Incidence: 6-10 cases / 100,000 population / year. Distribution male:female = 1:2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D69.3"
        },
        {
            "text": "IgG-mediated immune reaction (rarely IgM) against platelet membrane antigens, e.g., GPIIb / GPIIIa (fibrinogen receptor), GPIb / IX (von Willebrand receptor), and GPIa / IIa (collagen receptor).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D69.3"
        },
        {
            "text": "\u2022 Specific platelet antibodies detectable in approximately 50-70% of cases \u2022 Macrophage binding via Fc\u03b3 I, II, and III receptors (in ITP patients: receptor polymorphism with altered binding affinity for IgG) \u2022 Complement activation \u2022 Complement-mediated lysis and enhancement of phagocytosis \u2192 RES phagocytosis of IgG-coated platelets, esp. in spleen \u2192 Biological half-life of platelets \u2193\u2193 to a few hours \u2022 Decreased thrombocytopoiesis (antibodies against megakaryocytes and thrombopoietic progenitor cells) \u2022 Possibly T-cell-mediated process (in vitro, CD4 + T-cells can be activated by platelets)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D69.3"
        },
        {
            "text": "\u2022 Without known causative disease (\"primary ITP\") \u2022 In conjunction with an underlying disease (\"secondary ITP\"): lymphoproliferative diseases, autoimmune diseases (systemic lupus erythematosus, etc.), viral diseases (e.g., HCV, HIV), bacterial infections (esp. in children), after bone marrow transplantation",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Etiology"
        },
        {
            "text": "\u2022 Children: in > 90% of cases, \"acute\" course: severe thrombocytopenia, usually spontaneous remission within 3 months \u2022 Adults: in > 90% of cases, \"chronic\" course (thrombocytopenia > 6 months): < 5% risk of fatal hemorrhages (esp. intracranial), rarely spontaneous remission (5%), persists for more than 6 months despite adequate treatment in 35% of patients",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Progression"
        },
        {
            "text": "Thrombocytopenia with normal differential and morphology.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Blood Count"
        },
        {
            "text": "Normal or reactively increased megakaryocyte count, increased number of immature megakaryocytes. Otherwise, normal bone marrow, no abnormal cells.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bone Marrow"
        },
        {
            "text": "\u2022 Rare with platelet count > 30,000/\u00b5l . ITP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemorrhage"
        },
        {
            "text": "\u2022 Petechial type of hemorrhage (skin, mucous membranes), with hematomas / bruising / epistaxis \u2022 Complication: intracerebral hemorrhage (rare), organ bleeding, retinal bleeding, gastrointestinal bleeds",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A.K. Thomas, J. Heinz"
        },
        {
            "text": "The diagnosis of ITP is a diagnosis of exclusion. Therefore, the diagnostic strategies are aimed at identifying potential underlying causes of secondary thrombocytopenia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A.K. Thomas, J. Heinz"
        },
        {
            "text": "\u2022 Medical history, family history, drug exposure, occupational hazards \u2022 Physical examination (petechiae, bruising, mucosal bleeds)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clinical Diagnosis"
        },
        {
            "text": "\u2022 Full blood count with differential \u2022 Virology: HCV / HIV serology in patients at risk \u2022 Screening for platelet antibodies (50% positive)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "Bone marrow biopsy and smear in accordance with recommendations of ASH (American Society of Hematology) and BCSH (British Committee for Standards in Hematology):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "\u2022 Patients over 60 years of age \u2022 Laboratory abnormalities (neutropenia, anemia) \u2022 Prior to splenectomy \u2022 Poor response to primary treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Differential diagnosis of thrombocytopenia 7 Chap. 6.3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Only a small number of randomized studies have been conducted in ITP. The life expectancy of ITP patients with a platelet count > 30,000/\u00b5l is equal to that of the normal population. With higher platelet counts (30,000/\u00b5l), treatment is therefore only indicated if blood loss is expected (perioperatively, before delivery) or in the case of active hemorrhage. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Indications for Treatment"
        },
        {
            "text": "\u2022 Initial response rate > 50%, long-term effect in 30% of patients, low-dose maintenance treatment is required in most cases \u2022 Prednisolone 1-2 mg/kg daily, duration of treatment depending on response, or dexamethasone 40 mg/d for 4 days \u2022 With durable platelet response: dose reduction of prednisolone over 6-12 weeks, monitoring of platelet counts \u2022 If no increment to > 30,000/\u00b5l within 2-4 weeks or required steroid dose markedly above the threshold dose for Cushing's disease \u2192 change treatment to immunoglobulins or alternative immunosuppressive drugs",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Steroids"
        },
        {
            "text": "\u2022 Initial response rate 75%, normalization of the platelet count in 50% of patients; however, only transient (up to 4 weeks) \u2022 Standard dose: 0.4 g/kg daily i.v. days 1-5 or 1 g/kg daily i.v. day 1 + 2 \u2022 Alternative: anti-D IgG in Rh-positive patients, 75 \u00b5g/kg body weight over 2-3 days. Disadvantage: i.v. product not available in all countries, high costs",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunoglobulins (ivIG)"
        },
        {
            "text": "In cases of severe or life-threatening hemorrhage: combined administration of methylprednisolone 1 g daily i.v. over 3 days and immunoglobulins 0.4-1 g/kg daily over 2-4 days, platelet transfusion. Due to the short platelet half-life in ITP, the expected platelet need is approximately 2-3 times higher than in other forms of thrombocytopenia. In patients with uncomplicated ITP, platelet transfusions are, generally not indicated.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunoglobulins (ivIG)"
        },
        {
            "text": "Thrombopoietic agent, binds to TPO receptor and stimulates platelet production of the bone marrow. In Phase III studies in ITP, platelet responses in 80-90% of cases. Starting dose 1 \u00b5g/kg once weekly s.c., dose adjustment according to platelet counts. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Romiplostim"
        },
        {
            "text": "\u2022 Immunoapheresis \u2022 Rituximab (CD20 antibody)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Experimental Treatment"
        },
        {
            "text": ". ITP Acquired heparin-induced thrombocytopenia D69.5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Experimental Treatment"
        },
        {
            "text": "Incidence of HIT type II (see below) with intravenous use of unfractioned heparin (UFH): 2-5%, with use of low-molecular-weight heparin (LMWH): < 0.5%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Experimental Treatment"
        },
        {
            "text": "\u2022 Dose-dependent mild early-onset thrombocytopenia (platelet count 100,000-150,000/\u00b5l) in the initial 2-3 days of heparin treatment (UFH / LMWH) \u2022 Caused by minor heparin-induced platelet aggregation, no immunological genesis \u2022 Usually self-limiting (after 1-2 days) while heparin administration is ongoing \u2022 Frequency of up to 30%",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type I"
        },
        {
            "text": "\u2022 Dose-independent late-onset thrombocytopenia, 4-20 days after start of heparin treatment (UFH / LMWH). In patients previously exposed to heparin (< 100 days), reoccurrence within hours \u2022 Severe thrombocytopenia (platelets < 100,000/\u00b5l), median platelet count approximately 60,000/\u00b5l, rarely < 20,000/\u00b5l or decreased to < 50% of the initial count; worsening of thrombocytopenia if heparin treatment is continued \u2022 Thromboembolic complications up to 40 days after heparin administration \u2022 IgG antibodies mostly against the platelet factor 4 (PF4)-heparin complex \u2192 Immune complex formation \u2192 Platelet activation due to binding of the immune complex to the Fc receptor (Fc\u03b3 RIIA), PF4 release \u2192 Platelet aggregation, endothelial cell damage, thrombin activation \u2192 Thromboembolic complications (\"white clot syndrome\") Clinical relevance: HIT type II: \u2022 Main symptom: thrombophilia, not hemorrhage \u2022 Warning signs: exanthema or necrosis at injection site \u2022 High incidence (up to 53%) of venous and arterial thrombosis, renal dysfunction, pulmonary embolism, infarction (complications may occur weeks after discontinuation of heparin)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "\u2022 Exclusion of other causes of thrombocytopenia (7 Chap. 6 .3).",
            "cite_spans": [
                {
                    "start": 48,
                    "end": 58,
                    "text": "(7 Chap. 6",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "\u2022 Combination of a functional test (e.g., heparin-induced platelet activation, HIPA) with ELISA (detection of PF4-heparin complexes). \u2022 ATTENTION: if HIT II is clinically suspected, discontinue heparin immediately and use alternatives, even without positive test. The diagnosis of HIT is based on clinical findings. Tests serve as confirmatory tools only.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "Exclude other causes of thrombocytopenia (7 Chap. 6 .3)",
            "cite_spans": [
                {
                    "start": 41,
                    "end": 51,
                    "text": "(7 Chap. 6",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "Therapeutic intervention (with HIT type II):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "\u2022 Discontinue heparin treatment (UFH / LMWH). ATTENTION: exclude exposure to \"hidden\" heparin, e.g., coagulation factor products, \"heparin lock\" of central catheters \u2022 Anticoagulation must be continued for at least 4 weeks, using: \u2212 Danaparoid sodium: heparin-free heparinoid, ATIII-mediated inhibition of factor Xa, half-life 24 h, renal elimination, monitoring via factor Xa levels, no antidote available \u2212 Hirudin derivatives, e.g., lepirudin: bivalent direct thrombin inhibitor, half-life 1.5 h, renal elimination, monitoring via PTT, no antidote available . HIT",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heparin-induced Thrombocytopenia (HIT) Type II"
        },
        {
            "text": "Thrombocytopenic thrombotic microangiopathies with hemolytic anemia (microangiopathic hemolytic anemia, MAHA). Subtypes:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A.K. Kaskel, J. Heinz"
        },
        {
            "text": "\u2022 Thrombotic-thrombocytopenic purpura (TTP, Moschcowitz disease): main symptoms are microangiopathic hemolytic anemia, thrombocytopenia, and neurological symptoms; renal dysfunction in 50% of cases \u2022 Hemolytic-uremic syndrome (HUS, Gasser's disease): main symptoms are acute renal failure (renal microangiopathy, glomeruli are particularly affected) and hemolytic anemia; thrombocytopenia and neurological symptoms are less pronounced than in TTP \u2022 Toxic microangiopathic hemolytic anemia (toxic MAHA): after treatment with mitomycin C or high-dose chemotherapy It is not yet clear whether TTP and HUS are separate diseases or whether they are different manifestations of one syndrome. Due to the frequently overlapping symptoms, the more commonly used term is TTP-HUS (in adult patients). Exception: HUS in children after E. coli infection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A.K. Kaskel, J. Heinz"
        },
        {
            "text": "TTP: age peak 30-50 years, distribution male:female = 1:2 HUS: incidence 3-5 cases/100,000 children/year, age peak 1-5 years, distribution male:female = 1:1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "M31.1"
        },
        {
            "text": "\u2022 Acquired or congenital (total) dysfunction of the vWF-cleaving protease (= ADAMTS13; a disintegrin and metalloprotease with thrombospondin type-1 motifs; cleaves vWF between the amino acids 842 and 843), with unusually large von Willebrand factor multimers (UL-vWF-M), particularly in chronically recurrent TTP \u2022 Acquired TTP: autoimmune disease with anti-vWF protease autoantibodies \u2022 Associated with infections (HIV), pregnancy, postpartum, after allogeneic bone marrow transplantation, drugs (mitomycin C, cyclosporine, ticlopidine, clopidogrel, quinine), autoimmune diseases (SLE)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Thrombotic-Thrombocytopenic Purpura (TTP)"
        },
        {
            "text": "\u2022 Normal vWF protease activity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemolytic-Uremic Syndrome (HUS)"
        },
        {
            "text": "\u2022 Commonly associated with gastrointestinal infections caused by Shiga toxin or verotoxin-producing Escherichia coli (serotypes OH, particularly O157:H7, O103:HU, O103:H2), rarely shigella (Shigella dysenteriae serotype I). \u2022 In the absence of gastrointestinal infections, HUS is probably complement-mediated and occurs in connection with autosomal recessively inherited factor H mutations. In sporadic forms, factor H autoantibodies are thought to be involved. In this case, association with glomerulonephritis type II and involvement of autoantibodies against C3 convertase.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemolytic-Uremic Syndrome (HUS)"
        },
        {
            "text": "Under physiological conditions, vWF multimers are excreted by endothelial cells and deposited subendothelially. In the case of endothelial damage \u2192 complex formation of vWF multimers with thrombocytes \u2192 thrombocyte aggregation due to binding to platelet glycoproteins Ib, IX, and V as well as activated GP IIb/IIIa.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemolytic-Uremic Syndrome (HUS)"
        },
        {
            "text": "In cases of thrombotic microangiopathies, platelet aggregates or microthrombi are formed in capillaries and small vessels causing infarction, particularly in CNS and kidney.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemolytic-Uremic Syndrome (HUS)"
        },
        {
            "text": "\u2022 Thrombocytopenia due to peripheral destruction \u2022 Anemia due to mechanical destruction of erythrocytes in partially thrombosed small vessels (fragmentocytes, LDH \u2191, haptoglobin \u2193\u2193). . TTP-HUS Thrombotic microangiopathies constitute a hematological emergency \u2192 immediate specific treatment is of vital importance. Without adequate treatment, the mortality rate is 90%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemolytic-Uremic Syndrome (HUS)"
        },
        {
            "text": "\u2022 Plasma exchange via pheresis with fresh frozen plasma (FFP) initially 40 ml/kg daily \u2022 Aim: depletion of vWF multimers and autoantibodies, substitution of vWF protease (t\u00bd > 24 h) through FFP or as cryoprecipitate \u2022 Success parameters: normalization of LDH and platelets, regression of neurological symptoms; once laboratory parameters have normalized, lengthening of pheresis intervals \u2022 If symptoms persist: increase pheresis frequency to twice daily or raise volume to 80 ml/kg (in individual cases, as much as 140 ml/kg/day may be indicated \u2192 however, twice daily pheresis seems to be more effective); in addition, prednisone (1 mg/kg/day) or methylprednisolone (125 mg i.v. twice daily) and possibly vincristine or immunoglobulins \u2022 Pheresis is often accompanied by moderate citrate toxicity (muscle cramps, tetany) \u2192 calcium replacement \u2022 Even with adequate treatment, full reconstitution of renal function may be delayed ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Plasmapheresis"
        },
        {
            "text": "\u2022 With suspected acquired TTP: prednisolone 3 \u00d7 50 mg/day i.v. or p.o. over 1 week, withdraw gradually over a period of at least 4 weeks \u2022 Patients with acquired antibody-mediated TTP who respond insufficiently to plasmapheresis or have relapsed: additional immunosuppressive treatment, e.g., splenectomy, immunoadsorption via protein A column, possibly azathioprine or other immunosuppressives (e.g., anti-CD20 antibody rituximab \u00b1 cyclophosphamide, cyclosporine). \u2022 Congenital vWF protease deficiency: treatment according to symptoms: replacement of vWF protease \u00b1 plasmapheresis, prophylactic platelet aggregation inhibitors may be required with platelet recovery.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Additional Treatment Options"
        },
        {
            "text": "Platelet transfusion only after careful benefit-risk assessment (e.g., life-threatening hemorrhage) \u2192 possible deterioration of symptoms (increased intravascular thrombus formation). . TTP-HUS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ATTENTION:"
        },
        {
            "text": "Reduced hemoglobin concentration and hematocrit. Red blood cell (RBC) number below normal level. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hematology and Hemostasis Part"
        },
        {
            "text": "Substitution of packed red blood cells: restrictive indication (7 Chap. 4.9.1).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supportive Treatment"
        },
        {
            "text": "\u2022 Individual assessment of transfusion indication for each patient.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "\u2022 In acute blood loss, consider indication when hemoglobin < 8.0 g/dl.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "\u2022 With chronic anemia lower levels of hemoglobin (6-8 g/dl) are generally tolerated.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "\u2022 Patients with coronary heart disease or risk of cerebral ischemia: transfusion indication at hemoglobin < 10 g/dl. \u2022 Specific conditions (surgery, thalassemia major, etc.) may require RBC transfusion support.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "The indication for transfusion is based on clinical symptoms. Asymptomatic blood loss does not constitute an indication for transfusion.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "Anemias with decreased corpuscular hemoglobin (MCH < 28 pg) and decreased corpuscular hemoglobin concentration (MCHC < 32%):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "\u2022 Iron deficiency anemia (> 90% of hypochromic anemias) \u2022 Anemia of chronic disease (inflammation-/ infection-/ tumor anemia) \u2022 Thalassemia (7 Chap. 6.4 .3) \u2022 Rare causes: vitamin B6 deficiency, lead intoxication",
            "cite_spans": [
                {
                    "start": 140,
                    "end": 152,
                    "text": "(7 Chap. 6.4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Guidelines for Transfusion Indication"
        },
        {
            "text": "Iron deficiency anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Parameter"
        },
        {
            "text": "Most frequent form of anemia. Proportion male:female = 1:5. About 10-20% of women in childbearing age demonstrate latent iron deficiency.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Iron Deficiency Anemia"
        },
        {
            "text": "Daily iron resorption required: men 1 mg, women and adolescents 2-3 mg, pregnant women 3-4 mg. About 60-70% of body iron store bound in hemoglobin, additional 10% in myoglobin. 1 g hemoglobin contains 3.4 mg of iron.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Iron metabolism"
        },
        {
            "text": "In iron deficiency the iron need is greater than the available iron supply, resulting in hemoglobin synthesis disorders \u2192 microcytic, hypochromic erythrocytes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Iron metabolism"
        },
        {
            "text": "\u2022 Ferritin serum : correlates with total iron (\u2193 in iron deficiency) \u2022 Transferrin serum : correlates with circulating iron and need (\u2191 in iron deficiency)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Parameters"
        },
        {
            "text": "Most important cause: loss of iron due to chronic bleeding \u2192 in manifest iron deficiency evaluation of underlying cause is of central importance. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Parameters"
        },
        {
            "text": "Microcytic, hypochromic erythrocytes, poikilocytosis, anisocytosis, anulocytes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Peripheral Blood"
        },
        {
            "text": "Iron stain (Prussian blue stain): storage iron not detectable (ferritin, hemosiderin). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bone Marrow"
        },
        {
            "text": "\u2022 Skin and nail changes: skin atrophy, spoon-shaped nails (koilonychia) \u2022 Oral rhagades, impairment of mucous membranes, in extreme cases painful mucous membrane atrophy of tongue, pharynx, and esophagus with dysphagia (Plummer-Vinson syndrome)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptoms of Iron Deficiency"
        },
        {
            "text": "\u2022 History, esp. infections, drugs, bleeding, nutritional habits \u2022 Physical examination: including skin, mucous membranes, lymph node status, spleen / liver, heart (tachycardia, particularly systolic murmur), rectal examination with fecal blood test, urine dipstick \u2022 Gynecological examination \u2022 Endoscopy: esophago-gastro-duodenoscopy, colonoscopy, rectoscopy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "History, Clinical Findings"
        },
        {
            "text": "\u2022 Hematology: blood count, MCV \u2193, MCH \u2193, reticulocytes, differential blood count \u2022 Clinical chemistry: routine tests with bilirubin, renal function parameters, iron status (iron \u2193, ferritin \u2193, transferrin-binding capacity \u2191) \u2022 Blood group (if red cell substitution necessary) \u2022 Iron resorption test (if resorption deficiency is suspected)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "In inconclusive cases eventually bone marrow aspiration / biopsy, including iron staining, to exclude other causes of anemia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "\u2022 Anemia of chronic disease (iron \u2193, ferritin normal or elevated, transferrin-binding capacity \u2193) \u2022 Thalassemia (MCV \u2193\u2193, iron, ferritin, and transferrin-binding capacity normal) \u2022 Hemolytic anemia (bilirubin, LDH, haptoglobin, Coombs' test)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Treatment of anemia with iron deficiency always requires a combined approach: 1. Treatment of the underlying cause of iron deficiency (e.g., chronic blood loss) 2. Iron substitution ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "\u2022 Application of ferrous II preparation, e.g., Fe(II) sulfate, fumarate, gluconate, or succinate, 100-200 mg/day p.o., for 2-6 months. \u2022 PKIN: oral bioavailability, depending on preparation, 15-25%, better bioavailability when taken prior to food. \u2022 SE: gastrointestinal tract symptoms (nausea, vomiting,), dark discoloration of stool (ATTEN-TION misdiagnosis: upper gastrointestinal bleeding). \u2022 Treatment monitoring: after 5-7 days reticulocytes \u2191, hemoglobin \u2191. Most frequent cause of a treatment failure is lack of compliance, followed by combined anemia (e.g., coexisting iron deficiency and lack of vitamin B12).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Oral Iron Substitution"
        },
        {
            "text": "\u2022 Parenteral application of iron should be limited to individual cases (e.g., in malabsorption syndrome), due to severity of side effects. \u2022 Strictly intravenous application of ferrous(III) preparations, consider premedication with steroids and antihistaminics. \u2022 SE: thrombophlebitis, headache, flush, nausea, vomiting, fever, allergic reactions up to anaphylaxis. With paravenous injection local pain and visible iron deposits in tissue.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Parenteral Iron Substitution"
        },
        {
            "text": "Application of packed red blood cells is generally not indicated in iron deficiency anemia. Exceptions exist in patients with additional blood loss and clinical symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Red Cell Substitution"
        },
        {
            "text": "Second most common form of anemia (after iron deficiency anemia).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia Due to Inflammation, Infection, Tumor: Anemia of Chronic Disease (ACD)"
        },
        {
            "text": "Multifactorial anemia with chronic underlying disease (malignancy, inflammation, infection, collagen diseases). Pathogenetic factors:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia Due to Inflammation, Infection, Tumor: Anemia of Chronic Disease (ACD)"
        },
        {
            "text": "\u2022 Cytokine-mediated (TNF\u03b1, interleukin-1, interferon \u03b3) \u2192 erythrocyte-survival time \u2193, interference with iron mobilization from reticuloendothelial iron stores (macrophages), iron uptake / utilization in normoblasts \u2193, erythropoietin secretion and effect \u2193, inhibition of erythroid progenitor cells, etc. \u2022 Treatment-associated (drugs, radiation therapy, etc.) \u2022 Consequence of underlying disease",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia Due to Inflammation, Infection, Tumor: Anemia of Chronic Disease (ACD)"
        },
        {
            "text": "Normochromic, normocytic or hypochromic, microcytic red blood cells, poikilocytosis, anisocytosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Peripheral Blood"
        },
        {
            "text": "\u2022 Pallor of skin and mucous membranes, nail beds, conjunctivae \u2022 Weakness, tiredness, reduced performance, exertional dyspnea \u2022 Lack of concentration, headache",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptoms of Anemia"
        },
        {
            "text": "Depending on disease, generally with \u2022 Tiredness, weakness, reduced performance \u2022 Fever, weight loss, night sweats (B symptoms) \u2022 Loss of appetite, myalgia, arthralgia, etc. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptoms of Underlying Disease"
        },
        {
            "text": "In inconclusive cases consider bone marrow aspiration / biopsy, including iron staining, to exclude other causes of anemia. Anemia with increased erythrocyte volume (MCV > 98 fl), usually caused by lack of vitamin B12 (cobalamin) and/or folic acid.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Incidence 5-10 cases/100,000 population/year, distribution male:female = 3:2, age peak 60 years",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vitamin B12 Deficiency Anemia"
        },
        {
            "text": "The reference nutrient intake (RNI) for vitamin B12 is 1 \u00b5g, with maximum daily absorption in the terminal ileum of 2-3 \u00b5g. \"Intrinsic factor\" (glycoprotein) is a prerequisite for vitamin B12 resorption.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vitamin B12 metabolism"
        },
        {
            "text": "\u2022 Cofactor in the synthesis of succinyl CoA, methionine, and tetrahydrofolic acid \u2022 In case of vitamin B12 deficiency:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Function of Vitamin B12 (Cobalamin)"
        },
        {
            "text": "\u2192 DNA synthesis and fatty acid metabolism impaired \u2192 Delayed nuclear maturation, normal cytoplasmic development \u2192 Ineffective myelopoiesis, large cells with altered nucleus: plasma ratio",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Function of Vitamin B12 (Cobalamin)"
        },
        {
            "text": "\u2022 Most frequent cause: pernicious anemia (80% of cases): autoimmune atrophic gastritis with antibodies against gastric parietal cells (90% of cases) and/or antibodies against intrinsic factor (50% of cases) \u2192 Achlorhydria, intrinsic factor deficiency \u2192 Decreased vitamin B12 resorption in the terminal ileum \u2022 Insufficient vitamin B12 uptake (strict vegetarians, alcoholics) \u2022 Postoperatively (gastrectomy, resection of the terminal ileum, blind loop syndrome) \u2022 Vitamin B12 malabsorption, rare (Crohn's disease, scleroderma, amyloidosis) \u2022 Infections / parasites (fish tapeworm, bacterial gastrointestinal infections)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Causes of Vitamin B12 Deficiency"
        },
        {
            "text": "Macrocytic hyperchromic erythrocytes, poikilocytosis, anisocytosis, hypersegmented granulocytes (right shift); in severe cases, granulocytopenia and thrombocytopenia. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Peripheral Blood"
        },
        {
            "text": "Megaloblastic changes: ineffective left-shifted erythro-, thrombo-, and granulopoiesis, pronounced erythropoiesis with increased numbers of immature erythroid precursors (erythropoietic hyperplasia with megaloblastic erythroblasts), giant band forms, immature megakaryocytes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bone Marrow"
        },
        {
            "text": "\u2022 Pale skin and mucous membranes, icterus (due to intramedullary hemolysis) \u2022 Weakness, fatigue, reduced performance, dyspnea on exertion \u2022 Difficulty concentrating, headache",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia-related Symptoms"
        },
        {
            "text": "In advanced cases: funicular myelosis: neuropathy caused by symmetrical damage of the posterior columns of the spinal cord, the corticospinal tract and peripheral nerves; motor abnormalities mainly affecting the lower extremities; staggering gait, ataxia, spastic paresis, impaired vision, psychological disorders.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Neurological Symptoms"
        },
        {
            "text": "\u2022 Type A gastritis \u2022 Trophic disorders of the skin and mucous membranes: Hunter's glossitis, etc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Gastrointestinal and Other Symptoms"
        },
        {
            "text": "\u2022 Sterility (gonad dysfunction), reversible",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Gastrointestinal and Other Symptoms"
        },
        {
            "text": "\u2022 Medical history: infections, drugs, hemorrhage, nutritional habits \u2022 Physical examination: skin, mucous membranes, lymph node status, spleen / liver, heart (tachycardia, in some cases: systolic cardiac murmur), rectal examination and test for fecal blood, neurological examination",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "\u2022 Hematology: blood count with MCV (\u2191), MCH (\u2191), reticulocytes (\u2193), differential blood count \u2022 Clinical chemistry: liver and renal function tests, total protein, hemolysis parameters (bilirubin \u2191, LDH \u2191\u2191, haptoglobin \u2193 due to intramedullary hemolysis) \u2022 Antibodies against gastric parietal cells and/or against intrinsic factor \u2022 Vitamin B12 serum level (normal: 200-900 pg/ml), folic acid serum level \u2022 Vitamin B12 absorption test (Schilling's test): oral administration of radioactive B12 \u00b1 intrinsic factor, determination of urinary vitamin B12, comparison of vitamin B12 absorption / excretion with and without intrinsic factor \u2022 Blood group (if red cell transfusion is necessary)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "\u2022 Gastroscopy: detection of chronic atrophic gastritis, exclusion of gastric carcinoma (incidence 3 times higher with chronic atrophic gastritis) \u2022 Bone marrow aspiration / biopsy to confirm megaloblastic abnormalities",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "\u2022 Alcoholism (most common cause of a macrocytic blood count) \u2022 Hepatic disorders, severe hypothyroidism \u2022 Reticulocytosis, myelodysplasia (7 Chap. 7 ",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 148,
                    "text": "(7 Chap. 7",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Other Causes of Macrocytosis"
        },
        {
            "text": "Hydroxycobalamin 1 mg i.m. \u2192 initially: 6 injections within 2-3 weeks (to replenish vitamin B12 stores), then: one injection every 3 months. Additionally: application of ferrous II preparation and folic acid to cover increased erythropoesis during substitution phase. ATTENTION: close monitoring during the first days of treatment: critical increase in reticulocytes and platelets possible \u2192 increased risk of thrombosis, potassium and iron deficiency.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vitamin B12 Substitution"
        },
        {
            "text": "Gastroscopy at regular intervals due to increased risk of gastric cancer.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vitamin B12 Substitution"
        },
        {
            "text": "Reference nutrient intake (RNI) for folic acid: 100-200 \u00b5g, during pregnancy 400 \u00b5g.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Folic acid metabolism"
        },
        {
            "text": "\u2022 Folic acid is a cofactor of thymidylate synthesis (C1 transfer), i.e., DNA synthesis \u2022 In case of folic acid deficiency:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Function"
        },
        {
            "text": "\u2192 Disorder of DNA synthesis \u2192 Delayed nuclear maturation with normal cytoplasmic development \u2192 Ineffective myelopoiesis, giant cells with an abnormal nucleus: plasma ratio",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Function"
        },
        {
            "text": "\u2022 Insufficient folic acid intake: nutritional deficiency, alcoholism, anorexia nervosa \u2022 Malabsorption: gluten-induced enteropathy, tropical sprue, Crohn's disease, scleroderma, amyloidosis, postoperatively (small bowel resection, gastrectomy) \u2022 Increased demand: pregnancy, chronic hemolytic anemia, chronic inflammatory disease, or malignancies \u2022 Loss of folic acid: hemodialysis \u2022 Drug-induced (with folic acid antagonists): methotrexate, trimethoprim, pyrimethamine, phenytoin, triamterene",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Causes of Folic Acid Deficiency"
        },
        {
            "text": "See Vitamin B12 Deficiency Anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Peripheral Blood and Bone Marrow"
        },
        {
            "text": "\u2022 Pale skin and mucous membranes, icterus (due to intramedullary hemolysis) \u2022 Weakness, fatigue, reduced performance, dyspnea on exertion \u2022 Difficulty concentrating, headache",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia-related Symptoms"
        },
        {
            "text": "\u2022 Folic acid deficiency during pregnancy: increased incidence of neural tube defects (spina bifida, anencephaly) \u2022 Sterility (gonadal dysfunction), reversible ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Folic Acid Deficiency-related Symptoms"
        },
        {
            "text": "\u2022 Hematology: blood count with MCV (\u2191), MCH (\u2191), reticulocytes (\u2193), differential blood count \u2022 Clinical chemistry: liver and renal function tests, total protein, hemolysis parameters (bilirubin \u2191, LDH \u2191, haptoglobin \u2193 due to intramedullary hemolysis) \u2022 Vitamin B12 level, folic acid level (normal: 6-20 ng/ml) \u2022 Blood group (if red cell transfusion is necessary)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "\u2022 Esophago-gastro-duodenoscopy: exclusion of gluten-sensitive enteropathy (sprue) \u2022 Bone marrow aspiration / biopsy to confirm megaloblastic abnormalities See Vitamin B12 Deficiency Anemia Anemia caused by erythrocyte destruction characterized by decreased erythrocyte survival (< 120 days)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "In the bone marrow, 2 \u00d7 1011 erythrocytes are produced per day; median erythrocyte survival: 120 days; erythrocyte destruction in spleen and liver (reticuloendothelial system, RES).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Physiological Erythrocyte Turnover"
        },
        {
            "text": "Generally, normochromic normocytic anemia with normal leukocytes and platelets; characteristic changes in cases of hereditary membrane defects (spherocytes, elliptocytes, etc.); anisocytosis, poikilocytosis, and, in some cases, fragmentocytes. . Hemolytic Anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Peripheral Blood"
        },
        {
            "text": "Erythropoietic hyperplasia, increase in erythroblasts. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bone Marrow"
        },
        {
            "text": "Consider bone marrow aspiration / biopsy, including iron stain, to exclude other causes of anemia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Therapeutic options depend on the anemia subtype. Treatment components are: \u2022 Supportive treatment: red cell transfusion (only in individual cases with symptomatic anemia, controversial in cases of autoimmune hemolytic anemia) \u2022 Treatment of underlying disease \u2022 Immunosuppression (in cases of autoimmune hemolytic anemia) \u2022 Splenectomy \u2192 removal of the sequestration filter for damaged erythrocytes ATTENTION Splenectomy \u2022 Splenectomy can correct the decrease in erythrocyte survival, but it is not a causal therapy in the sense of a correction of the triggering hemolytic defect. \u2022 Prior to splenectomy, MANDATORY vaccination against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae because of the sepsis risk. \u2022 After splenectomy, prevention of thromboembolic events (platelets \u2191) \u2192 low-dose heparin.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Histology"
        },
        {
            "text": "Most common hereditary hemolytic disease; prevalence 0.02%; in most cases hereditary disease (autosomal dominant), spontaneous mutation is rare. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hereditary Spherocytosis"
        },
        {
            "text": "Rare, higher incidence in Mediterranean countries / Africa (increased malaria resistance of elliptocytes)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hereditary Elliptocytosis"
        },
        {
            "text": "Heterogenic disease group with > 25% of elliptic erythrocytes; protein defects of the erythrocytic cytoskeleton (spectrin, protein 4.1R)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hereditary Elliptocytosis"
        },
        {
            "text": "Usually asymptomatic; only 10-30% of patients have varying degrees of anemia, icterus or hemolytic crises",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hereditary Elliptocytosis"
        },
        {
            "text": "\u2022 Positive family history \u2022 Blood smear with > 25% elliptocytes In symptomatic patients: splenectomy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hereditary Elliptocytosis"
        },
        {
            "text": "Acquired clonal disorder of myeloid stem cells (i.e., of the erythrocytic, granulocytic, and thrombocytic line) with somatic mutations of phosphatidylinositol-glycan A (PIG A) \u2192 defect of the \"phosphatidylinositol-glycan anchor\" (PIG anchor)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Paroxysmal Nocturnal Hemoglobinuria"
        },
        {
            "text": "The PIG anchor fixes various proteins to the cell membrane, including three complement-regulating proteins: CD59 (membrane inhibitor of reactive lysis; MIRL), CD55 (decay accelerating factor; DAF), and \"C8 binding protein\" (CBP). \u2192 Changes in the PIG anchor lead to a decrease in the respective proteins in the cell membrane \u2192 Reduced resistance against activated complement factors \u2192 Complement-mediated lysis \u2191, incidence of thromboembolic events \u2191",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Paroxysmal Nocturnal Hemoglobinuria"
        },
        {
            "text": "\u2022 Chronic hemolytic anemia \u2022 Different severity levels of nocturnal hemolysis (even nocturnal hemolytic crises), with morning hemoglobinuria \u2022 Recurrent thrombosis, particularly portal vein, liver veins (Budd-Chiari syndrome), cerebral vessels, splenic vein, skin veins (skin necrosis) \u2022 Iron deficiency anemia due to chronic loss of iron (renal)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Paroxysmal Nocturnal Hemoglobinuria"
        },
        {
            "text": "\u2022 Medical history: circadian occurrence of symptoms \u2022 Physical examination: anemia signs and symptoms, urinary discoloration",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "\u2022 Normochromic normocytic anemia, in some cases with granulocytopenia and thrombocytopenia \u2022 Hemolysis parameters (LDH \u2191, haptoglobin \u2193, indirect bilirubin \u2191, hemoglobinuria) \u2022 Acid hemolysis test (Ham's test) and sugar water test (sucrose test), pathological: complementmediated lysis after addition of sugar water or acid to the blood sample \u2022 Molecular genetic proof of the PIG defect In rare cases development of aplastic anemia, myelodysplasia, or AML",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "\u2022 Prophylactic anticoagulant therapy: phenprocoumon. ATTENTION: avoid heparin \u2192 possible complement activation \u2022 Iron and folic acid supplementation \u2022 In cases of hemolytic crisis: corticosteroids (prednisolone 50-100 mg i.v.), supportive treatment \u2022 Blood transfusion: only washed erythrocytes to avoid administration of additional complement \u2022 Eculizumab, antibody against complement c5, inhibits complement-mediated lysis of PNH erythrocytes",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supportive Approach"
        },
        {
            "text": "Allogeneic stem cell transplantation (7 Chap. 5. 3): only in severe cases with repeated hemolytic crises or complications (thromboembolic events, etc.)",
            "cite_spans": [
                {
                    "start": 37,
                    "end": 48,
                    "text": "(7 Chap. 5.",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Curative Approach"
        },
        {
            "text": "Hereditary disease, genetic modification of the glucose-6-phosphate dehydrogenase (> 300 mutants worldwide)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Glucose-6-phosphate Dehydrogenase Deficiency (G6PD Deficiency, Favism)"
        },
        {
            "text": "One of the most common hereditary diseases worldwide, regional differences in incidence and prevalence. In Africa, Asia, and the Mediterranean region, as much as 20-60% of the population may be affected (patients are more resistant to malaria plasmodia). X-chromosomal recessive inheritance \u2192 mainly males affected. Heterozygotics have two different populations of erythrocytes and usually have less pronounced symptoms. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Glucose-6-phosphate Dehydrogenase Deficiency (G6PD Deficiency, Favism)"
        },
        {
            "text": "Hereditary defect of the enzyme pyruvate kinase, i.e., the erythrocytic glycolysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Most common hereditary glycolytic defect (Embden-Meyerhof pathway), autosomal recessive inheritance. Heterozygotic individuals are usually asymptomatic. Homozygosis (rare) leads to hemolytic anemia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Pyruvate kinase deficiency results in abnormal glycolysis: \u2192 ATP deficiency \u2192 abnormal Na + / K + -ATPase activity in the erythrocyte membrane \u2192 Membrane instability, hemolysis Usually asymptomatic. In homozygotic individuals, hemolytic crises may occur.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "\u2022 Blood smear with acanthocytes, anisocytosis, poikilocytosis \u2022 Hemolysis parameters, reduced erythrocytic pyruvate kinase activity Symptomatic patients: splenectomy; in cases of iron overload: venesection therapy and administration of desferrioxamine.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Hemoglobin S (HBS): point mutation in the \u03b2-globin locus (chromosome 11) of the hemoglobin molecule in position 6: replacement of glutamic acid by valine (\u03b26 Glu \u2192 Val).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "HBS precipitates when deoxygenated (risk factors: lack of oxygen, dehydration, fever, increased serum osmolality, stasis): \u2192 Sickle-shaped erythrocytes with reduced elasticity \u2192 Hemolysis, disturbed microcirculation, capillary occlusion Heterozygotic individuals (HBAS) are usually asymptomatic. In homozygotic cases (HBSS):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "\u2022 Hemolytic anemia and hemolytic crisis \u2022 Vaso-occlusive crises: organ infarction (particularly spleen, kidney, CNS), bone infarction, pulmonary hypertension \u2022 Abdominal pain, bone pain, cerebral disorders, in some cases with fever, tachycardia, leucocytosis \u2022 Hepatosplenomegaly, recurrent splenic infarction \u2192 \"autosplenectomy, \" functional asplenia \u2022 Osteoporosis, growth defects due to recurrent bone infarction \u2022 Pure red cell aplasia / aplastic crisis with parvovirus B19 infections \u2022 Proliferative retinopathy \u2192 impaired vision \u2022 Bilirubin gall stones \u2022 Immunodeficiency (due to recurrent splenic infarction)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "\u2022 Medical history (family history), clinical examination \u2022 Hemoglobin electrophoresis \u2022 Sickle cell test: erythrocytes show sickle shape after addition of sodium sulfide \u2022 Molecular genetic screening (PCR)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Other hemoglobinopathies: more than 450 hemoglobinopathies have been described. HB C, E, and D are the most common.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Sickle cell anemia is treated supportively: \u2022 Fluid replacement, at least 2,000 ml/day \u2022 Oxygen (via nasal tube, 3-4 l/min) \u2022 Treatment of infections, analgesia \u2022 Red cell transfusion, in case of severe complications: exchange transfusion \u2022 In cases of splenic infarction / hemorrhage / rupture: splenectomy \u2022 Prophylactic pneumococcus vaccination \u2022 Hydroxyurea Prevention of lack of oxygen, dehydration, and infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pyruvate Kinase Deficiency (PK Deficiency)"
        },
        {
            "text": "Quantitative disturbance of hemoglobin synthesis due to a genetic defect in globin chain formation. Subtypes: \u2022 \u03b2-Thalassemia: abnormal \u03b2-chain synthesis \u2022 \u03b1-Thalassemia: abnormal \u03b1-chain synthesis (rare) Regional differences in incidence: \u03b2-thalassemia in Mediterranean regions, Africa, and Asia; \u03b1thalassemia in South East Asia and Africa.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u03b2-Thalassemia"
        },
        {
            "text": "Abnormal synthesis of the hemoglobin \u03b2-chain, i.e., no formation of normal adult HBA1 (\u03b1\u03b1/\u03b2\u03b2). \u2192 Compensatory formation of \u03b3-or \u03b4-chains (HBF = \u03b1\u03b1/\u03b3\u03b3 and HBA2 = \u03b1\u03b1/\u03b4\u03b4) \u2192 Ineffective erythropoiesis (free \u03b1-globin is toxic for erythroblasts) with intramedullary hemolysis \u2192 Hypochromic microcytic anemia, signs of hemolysis . Hemolytic Anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u03b2-Thalassemia"
        },
        {
            "text": "Hematology and Hemostasis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Part"
        },
        {
            "text": "Usually, no clinical symptoms; in some cases minor chronic hemolysis, anemia, and splenomegaly.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Heterozygotic Patients: Thalassemia Minor"
        },
        {
            "text": "\u2022 Chronic hemolysis, icterus \u2022 Hepatosplenomegaly \u2022 Cardiac insufficiency \u2022 Infections",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Homozygotic Patients: Thalassemia Major (Cooley's Anemia)"
        },
        {
            "text": "\u2022 Microcytic hypochromic anemia (HB \u2193, HCT \u2193, MCV \u2193, MCH \u2193) \u2022 Iron serum \u2191, ferritin \u2191, transferrin iron-binding capacity \u2193 \u2022 Blood smear: microcytic hypochromic erythrocytes, target cells, polychromasia, isolated normoblasts \u2022 Chronic erythropoietic bone marrow hyperplasia \u2192 expanded marrow, detectable in bone marrow scan or skull x-ray (\"hair-on-end\" sign) \u2022 Hemoglobin electrophoresis: increase in HBF (\u03b1\u03b1/\u03b3\u03b3) and HBA2 (\u03b1\u03b1/\u03b4\u03b4) \u2022 Molecular genetic detection of the defective globin gene (via PCR) Iron deficiency anemia (7 Chap. 6.4.1) .",
            "cite_spans": [
                {
                    "start": 524,
                    "end": 539,
                    "text": "(7 Chap. 6.4.1)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Homozygotic Patients: Thalassemia Major (Cooley's Anemia)"
        },
        {
            "text": "\u2022 RBC transfusion \u2022 Hemosiderosis treatment: desferrioxamine 2,000 IU/day s.c.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supportive Approach"
        },
        {
            "text": "In homozygotic cases / severe hemolysis: allogeneic stem cell transplantation during infancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Curative Approach"
        },
        {
            "text": "Autoimmune hemolytic anemia caused by IgG incomplete \"warm\" autoantibodies (incomplete antibodies: antigen-antibody binding, but no lysis or agglutination).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Warm Antibody Autoimmune Hemolysis (AIHA)"
        },
        {
            "text": "Seventy-five percent of all autoimmune hemolytic anemias.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Warm Antibody Autoimmune Hemolysis (AIHA)"
        },
        {
            "text": "\u2022 In non-Hodgkin's lymphoma, particularly in low-malignant NHL (CLL) \u2022 With autoimmune diseases, e.g., systemic lupus erythematosus (SLE) \u2022 Following infections (viral infections, rarely bacterial infections) \u2022 Drug-induced hemolysis (various mechanisms): antibiotics, \u03b1-methyldopa, L-dopa, quinine, quinidine, x-ray contrast agents, procainamide, diclofenac \u2022 Idiopathic (50% of cases)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Formation of IgG Warm Autoantibodies"
        },
        {
            "text": "\u2022 Binding of incomplete antibodies to erythrocytes \u2022 Destruction of antibody-coated erythrocytes in spleen and liver (extravascular non-complement-mediated lysis by cells of the reticuloendothelial system)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autoimmune Hemolysis"
        },
        {
            "text": "\u2022 Hemolysis and hemolytic crises, with icterus, hemoglobinuria, fever, etc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autoimmune Hemolysis"
        },
        {
            "text": "\u2022 Anemia symptoms (fatigue, weakness, reduced performance, pallor, headache, etc.)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autoimmune Hemolysis"
        },
        {
            "text": "\u2022 Case history including medication \u2022 Physical examination including signs and symptoms of anemia ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Case History, Physical Examination"
        },
        {
            "text": "Treatment of underlying disease or discontinuation of causative drugs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Causal Treatment"
        },
        {
            "text": "\u2022 Corticosteroids (prednisolone 100-500 mg/day i.v.), slowly taper dose after hemolysis parameters have normalized \u2022 In cases of chronic hemolysis and poor response to corticosteroids: use alternative immunosuppressive agents, e.g., azathioprine 80 mg/m2/day, cyclophosphamide 60 mg/m2/day p.o. \u2022 Splenectomy: in cases of treatment-refractory chronic hemolysis or refractory acute hemolytic crisis \u2022 Transfusion of packed red cells only in cases of symptomatic anemia (e.g., cardiovascular symptoms, dyspnea, cerebral ischemia)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptomatic Treatment"
        },
        {
            "text": "Autoimmune hemolytic anemia caused by IgM complete \"cold\" autoantibodies, usually targeting the I-antigen of the erythrocyte membrane (complete antibodies: capable of agglutination and lysis induction after antigen-antibody binding).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cold Agglutinin Autoimmune Hemolysis (AIHA)"
        },
        {
            "text": "Fifteen percent of all autoimmune hemolytic anemias.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cold Agglutinin Autoimmune Hemolysis (AIHA)"
        },
        {
            "text": "\u2022 In low-malignant non-Hodgkin's lymphoma or Hodgkin's disease \u2022 After infection (viral infections, mononucleosis / EBV infection, mycoplasma pneumoniae) \u2192 cold agglutinin titer up to 1:1,000",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Formation of Polyclonal Cold Autoantibodies (Cold Agglutinin Syndrome)"
        },
        {
            "text": "Rare congenital disease \u2192 Cold agglutinin titer up to 1:256,000",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary Formation of Monoclonal Cold Autoantibodies (Cold Agglutinin Disease)"
        },
        {
            "text": "When the intravascular temperature drops to < 20-25\u00b0C: antigen-antibody binding, agglutination and complement-mediated intravascular hemolysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autoimmune Hemolysis"
        },
        {
            "text": "\u2022 Exposure to cold leads to hemolysis and hemolytic crisis (with icterus, hemoglobinuria, fever, etc.) \u2022 Anemia symptoms (fatigue, weakness, reduced performance, pallor, headache, etc.) \u2022 Acrocyanosis: painful / malperfused extremities (fingers / toes / nose) \u2022 Splenomegaly . Hemolytic Anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Autoimmune Hemolysis"
        },
        {
            "text": "Hematology and Hemostasis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Part"
        },
        {
            "text": "\u2022 Medical history, physical examination \u2022 Diagnostic clues: erythrocyte agglutination when blood is drawn and during laboratory analysis \u2022 Anemia (HB \u2193, HCT \u2193), signs of hemolysis (LDH \u2191, indirect bilirubin \u2191, haptoglobin \u2193), detection of cold autoantibodies \u2022 Exclusion of potential underlying diseases \u2022 Blood group",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Part"
        },
        {
            "text": "Treatment of the underlying disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Causal Approach"
        },
        {
            "text": "\u2022 Protection against cold \u2022 With severe acute hemolysis: plasmapheresis (objective: removal of autoantibodies), often technically difficult (due to agglutination within the plasmapheresis system) \u2022 With chronic hemolysis: immunosuppressive drugs, e.g., azathioprine, cyclophosphamide, or chlorambucil \u2022 With symptomatic anemia (cardiovascular symptoms, dyspnea, cerebral malperfusion, etc.):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptomatic Approach"
        },
        {
            "text": "transfusion of washed packed red cells (avoid complement administration in cases of complement-mediated hemolysis) \u2022 Corticosteroids and splenectomy are usually ineffective Anemia with normal corpuscular hemoglobin (MCH 27-34 pg) and normal corpuscular hemoglobin concentration (MCHC 31-36 g/dl).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptomatic Approach"
        },
        {
            "text": "\u2022 Hemolytic anemia (7 Chap. 6.4 .3) \u2022 Aplastic anemia (7 Chap. 6.1) \u2022 Acute posthemorrhagic anemia \u2022 Renal anemia",
            "cite_spans": [
                {
                    "start": 19,
                    "end": 31,
                    "text": "(7 Chap. 6.4",
                    "ref_id": null
                },
                {
                    "start": 54,
                    "end": 67,
                    "text": "(7 Chap. 6.1)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Symptomatic Approach"
        },
        {
            "text": "Normochromic normocytic hyporegenerative anemia as a result of chronic renal failure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Renal Anemia"
        },
        {
            "text": "Incidence: 50-60 cases/100,000 per year.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Renal Anemia"
        },
        {
            "text": "\u2022 Complex pathogenesis based on renal insufficiency \u2022 Renal erythropoietin synthesis \u2193, the degree of anemia correlates with the severity of the underlying disease \u2022 Myelosuppresion and intramedullary hemolysis due to accumulation of uremic toxins \u2022 Concurrent chronic blood loss due to hemodialysis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Chronic Renal Failure Anemia"
        },
        {
            "text": "\u2022 Pale skin and mucous membranes \u2022 Weakness, fatigue, reduced performance, dyspnea on exertion \u2022 Difficulty concentrating, headache",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anemia Symptoms"
        },
        {
            "text": "\u2022 Uremic fetor \u2022 \"Caf\u00e9 au lait\" complexion due to urochrome deposits and concurrent anemia, pruritus \u2022 Weakness, headache",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Uremia Symptoms"
        },
        {
            "text": "\u2022 Medical history: signs of chronic renal insufficiency \u2022 Physical examination: skin, mucous membranes, lymph node status, spleen / liver, heart (tachycardia, systolic heart murmur), rectal examination and testing for fecal occult blood",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "\u2022 Hematology: blood count including MCV (normal), MCH (normal), reticulocytes (\u2193), differential blood count \u2022 Clinical chemistry: hepatic and renal function tests, total protein, hemolysis parameters (bilirubin, LDH, normal haptoglobin, low-grade hemolysis due to uremic toxins) \u2022 Vitamin B12 level, folic acid level \u2022 Serum iron, ferritin, transferrin; in cases of chronic blood loss due to hemodialysis, iron deficiency may occur \u2022 Erythropoietin \u2193 / normal (i.e., inadequate increase given the degree of anemia) \u2022 Blood group (if red cell transfusion is required)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Tests"
        },
        {
            "text": "\u2022 Erythropoiesis stimulation with darbepoetin 1.35 \u00b5g/kg body weight once weekly s.c. or i.v., adjust dose according to hemoglobin response \u2022 Alternatively, recombinant erythropoietin, 50 IU/kg body weight three times weekly s.c. or i.v., adjust dose according to hemoglobin response . Normochromic Anemia",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptomatic Treatment"
        },
        {
            "text": "\u2022 Target hemoglobin 10-12 g/dl \u2022 ATTENTION: blood pressure may rise as hematocrit increases, especially in cases of pre-existing hypertension \u2022 Hemodialysis \u2022 Additional iron supplementation with signs of iron deficiency (7 Chap 6.4.1) Causal Treatment ",
            "cite_spans": [
                {
                    "start": 221,
                    "end": 235,
                    "text": "(7 Chap 6.4.1)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "R. Engelhardt, J. Heinz"
        },
        {
            "text": "\u2022 Vasoconstriction \u2022 Platelet adhesion to endothelial lesion, aggregation, clot formation (primary hemostasis) \u2022 Coagulation cascade, fibrinogenesis (secondary hemostasis) \u2022 Fibrinolysis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Components of Hemostasis after Vascular Injury"
        },
        {
            "text": "Coagulation and fibrinolysis are physiologically balanced and are regulated by activators and inhibitors.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Components of Hemostasis after Vascular Injury"
        },
        {
            "text": "The distinction of an extrinsic and intrinsic system is artificial and not relevant for the physiological situation (in vivo). However, it helps to understand in vitro phenomena and clotting laboratory tests (Quick's value, PTT).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation cascade"
        },
        {
            "text": ". Coagulation Disorders",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Def: Def:"
        },
        {
            "text": "\u2022 Antithrombin (AT): prevention of excessive thrombin activation by formation of thrombin-AT complex, inhibition of IIa, IXa, Xa, XIa, XIIa; important physiological coagulation inhibitor; AT deficiency constitutes an increased risk of thrombosis (thrombophilia, 7 Chap. 6.6) \u2022 Protein C: thrombin-induced conversion into active protein C (APC); APC inhibits FVa and FVIIIa and induces the release of tPA (plasminogenic activator); protein C deficiency constitutes an increased risk of thrombosis (7 Chap. 6.6) \u2022 Protein S: cofactor of protein C \u2022 Heparin: activation of physiological AT \u2192 inhibition of thrombin generation; ineffective in cases of AT deficiency. Unfractionated (UFH) and low molecular weight (LMWH) heparins \u2022 Hirudin: direct thrombin inactivation, effective in cases of AT deficiency \u2022 Coumarin: vitamin K antagonists; inhibition of the hepatic synthesis of the factors II, VII, IX, and X as well as the proteins C and S ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation cascade inhibitors"
        },
        {
            "text": "\u2022 Acetylsalicylic acid: irreversible cyclooxygenase inhibition \u2022 Ticlopidine: inhibition of fibrinogen binding by interaction with GPIIb/IIIa \u2022 Tirofiban hydrochloride: GPIIb/IIIa receptor antagonist \u2022 Dipyridamole: increases the level of cellular cyclic AMP (cAMP) \u2022 Clopidogrel: selective inhibition of ADP binding, inhibition of ADP-mediated activation of the GPIIb/IIIa receptor complex",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inhibitors of Platelet Aggregation"
        },
        {
            "text": "Vitamin K Deficiency or Abnormal Synthesis of Vitamin K-dependent Clotting Factors (7 Chap. 6.5.1) \u2022 Severe liver damage \u2022 Antibiotic treatment, malabsorption syndrome, abnormal fat absorption, alcoholism Coagulopathies which may occur spontaneously or as a result of an underlying disease which is not primarily related to the hemostatic system. In contrast to primary disorders, several components of the hemostatic system are usually affected. Impaired synthesis and metabolic defects can be distinguished. ",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 98,
                    "text": "(7 Chap. 6.5.1)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Classification of Acquired and Congenital Coagulopathies"
        },
        {
            "text": "The liver is the primary site of formation and elimination of coagulation factors and their inhibitors as well as filtration \u2192 hepatic dysfunction can lead to complex hemostatic disorders:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation Disorders in Hepatic Diseases"
        },
        {
            "text": "\u2022 Impaired synthesis of clotting factors \u2192 factor deficiency (esp. factor II, V, VII, IX, X, XIII, fibrinogen, plasminogen, \u03b12-antiplasmin, antithrombin, protein C, protein S) \u2022 Impaired elimination of clotting factors \u2192 factor excess (e.g., VIII, von Willebrand-factor) \u2022 Impaired thrombopoiesis / platelet function (hypersplenism, bone marrow defect due to toxic effects of alcohol, vitamin B12 / folic acid deficiency, thrombopoietin deficiency) \u2022 Hyperfibrinolysis \u2022 Ascites \u2192 loss of coagulation factors (loss of coagulation factors via ascites)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation Disorders in Hepatic Diseases"
        },
        {
            "text": "\u2022 Signs of hepatic failure \u2022 Bleeding signs and symptoms: hematomas, mucous membrane hemorrhage, epistaxis \u2022 Esophageal variceal bleeding (life-threatening)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation Disorders in Hepatic Diseases"
        },
        {
            "text": "\u2022 Quick's test \u2193 (earliest indication of hepatic coagulation defects: includes factor VII which is the first to decrease due to its short half life of 6 h); suitable parameter for monitoring hepatic disorders \u2022 aPTT: may be normal or increased in advanced hepatic disorders \u2022 Platelets \u2193, fibrinogen \u2193, factor V \u2193, protein C \u2193, protein S \u2193, antithrombin \u2193 (may be increased in case of cholestasis), D-dimers \u2191 \u2022 Determination of separate factors usually not required",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Coagulation Disorders in Hepatic Diseases"
        },
        {
            "text": "\u2022 Initial treatment with fresh frozen plasma (FFP) 10 ml/kg. \u2022 If insufficient: antithrombin supplementation, fibrinogen supplementation (for levels below 1.0 g/l), administration of cryoprecipitate. \u2022 Administration of platelet concentrates, desmopressin (DDAVP; 0.4 \u00b5g/kg) and antifibrinolytics (e.g., aprotinin 250,000 IU in 30 min, 2 million IU/day i.v.) may be considered. ATTEN-TION: DIC (7 Chap. 6.5.5) . \u2022 If factor XIII concentration < 50% and FFP is without effect: administration of factor XIII concentrate. \u2022 If initial values are unknown / emergency situations: empirical treatment with antithrombin 50 IU/kg, fibrinogen 3 g, and PPSB 50 IU/kg. In cases of severe hemorrhage, treatment with activated factor VIIa may be considered. ",
            "cite_spans": [
                {
                    "start": 394,
                    "end": 409,
                    "text": "(7 Chap. 6.5.5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Acute Hemorrhage"
        },
        {
            "text": "Administration of antifibrinolytics (e.g., tranexamic acid 1 g three times daily), vitamin K ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Prophylaxis of Hemorrhage"
        },
        {
            "text": "Antibodies to clotting factors, occurring as primary (spontaneous) or secondary (due to underlying disease) antibodies: \u2022 Autoantibodies \u2212 Inhibitors to individual clotting factors (most commonly to factor VIII, antigen-induced hemophilia) \u2212 Antiphospholipid antibodies (7 Chap. 6.6) \u2212 Monoclonal immunoglobulins, heparin-like antibodies \u2022 Alloantibodies (inhibitors in hemophilia A / B replacement therapy) Incidence of factor VIII inhibitors 1:1,000,000 Acquired factor VIII inhibitors: 50% of cases occur spontaneously, secondary inhibitors in conjunction with: ",
            "cite_spans": [
                {
                    "start": 270,
                    "end": 283,
                    "text": "(7 Chap. 6.6)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Acquired Factor VIII Inhibitor (Antigen-induced Hemophilia)"
        },
        {
            "text": "Asparaginase therapy of acute leukemias \u2022 Impaired synthesis of clotting factors (esp. fibrinogen, antithrombin, protein C and S, factors II, IX, and XIII) \u2022 Potential complication: DIC (7 Chap. 6.5.5) Hemorrhages of all degrees and in all locations (hematomas, mucous membrane hemorrhage, postoperative bleeding) Levels of fibrinogen, antithrombin, D-dimers . Acquired Coagulation Disorders",
            "cite_spans": [
                {
                    "start": 186,
                    "end": 201,
                    "text": "(7 Chap. 6.5.5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Hemorrhagic Disorders with Asparaginase Treatment"
        },
        {
            "text": "Hereditary bleeding disorder caused by deficiency (90% of cases) or inactivity (10%) of coagulation factor VIII (FVIII, AHG-A, antihemophilic globulin A).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemorrhagic Disorders with Asparaginase Treatment"
        },
        {
            "text": "Most common hereditary coagulopathy, incidence 1 case/5,000 men/year. Women are heterozygotic carriers of the gene. Clinically apparent hemophilia in women is rare. Ratio between hemophilia A and B approximately 5:1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D66"
        },
        {
            "text": "\u2022 Factor VIII coding gene located on the X chromosome \u2192 mainly men are affected, X-linked recessive inheritance (70% of cases) or spontaneous mutations (30%) \u2022 Synthesis in liver, 265 kDa protein, no vitamin K dependence; half-life: 8-12 h \u2022 Factor VIII circulates in the plasma bound to von Willebrand factor (vWF) \u2192 protection from proteolytic degradation ATTENTION: Treatment must be provided as early as possible and must be sufficient with respect to dosage and treatment period.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D66"
        },
        {
            "text": "DDAVP, nasal spray, or intravenous administration (0.3-0.4 \u00b5g/kg in 100 ml saline over 30 min, every 12-24 h); effect occurs within 30-60 min: transient FVIII increase by factor 2-3 for up to 4 days; may also be given prior to minor surgery (e.g., tooth extraction), possibly with antifibrinolytics.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mild Bleeding and FVIII > 15-40%"
        },
        {
            "text": "Administration of recombinant factor VIII or plasma factor VIII. Administration of recombinant factor products excludes the risk of viral contamination (HBV, HCV, HIV, HSV, EBV, CMV, etc. (FEIBA) 20-100 IU/kg body weight every 8-12 h. In emergency situations: plasmapheresis or immunoadsorption Normal life expectancy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Severe Bleeding and/or Patients with FVIII < 15%"
        },
        {
            "text": "\u2022 Early detection of signs of bleeding \u2022 Controlled exercise and sports program to prevent bleeding into joints and to maintain mobility \u2022 Avoid platelet aggregation inhibitors (ASS, etc.), no intramuscular injections \u2022 Caries prophylaxis, meticulous local hemostasis during surgical procedures; no surgery without prophylactic administration of FVIII \u2022 Hepatitis A/B vaccination is recommended \u2022 X-linked inheritance \u2192 examine coagulation status of patient's relatives",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patient information and instruction are the best and most important bleeding prophylaxis"
        },
        {
            "text": "Bleeding-related arthropathy often goes unnoticed \u2192 close monitoring, permanent FVIII treatment in cases of severe hemophilia: 25-40 IU/kg 1-3 times weekly \u2192 rate of complications / arthroplasty significantly decreased.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "\u2022 Severe bleeding / planned operation: increase factor IX for 3 days to > 70% , then keep at > 50% for 7 days \u2022 In cases of emergency, fresh frozen plasma (FFP) may be used, if recombinant FIX concentrate is not available",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "\u2022 aPTT monitoring is not sufficient, plasma factor IX should be determined (shortly after replacement and before administration of the next dose) \u2022 1-4% of patients develop antibodies against infused factor, with treatment resistance \u2192 monitoring via FVII inhibitor assay Normal life expectancy Patient information and instruction (7 Chap. 6.5.2) ",
            "cite_spans": [
                {
                    "start": 331,
                    "end": 346,
                    "text": "(7 Chap. 6.5.2)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of FIX Replacement"
        },
        {
            "text": "Bleeding-related arthropathy often goes unnoticed \u2192 close monitoring, prophylactic factor IX treatment in cases of severe hemophilia in children: 25-40 IU/kg 2 times weekly \u2192 significant decrease of complication / arthropathy rate.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "Hereditary coagulopathy due to qualitative or quantitative deficiencies of the von Willebrand factor (vWF).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "D68.0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "Most common hereditary coagulopathy, heterozygotic gene carriers 1:100 to 1:1,000; incidence of symptomatic cases: 125 cases/1,000,000 population.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "Von Willebrand factor is a heterogenic multimeric plasma glycoprotein (normal serum level: 10 mg/l). The vWF precursor is synthesized as a monomer in the endothelium and megakaryocytes. Active forms (vWF multimers) are found in the endothelium, platelets, and plasma. Functions:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "\u2022 Mediation of platelet adhesion to vascular wall (collagen) via high-molecular vWF multimers and binding to platelet glycoprotein Ib (GPIb) \u2022 Factor VIII carrier in plasma",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "Hereditary defect caused by mutation in the vWF gene (chromosome 12); autosomal-dominant (subtype 1 and 2) or autosomal-recessive (subtype 2 and 3) inheritance. Consequences: \u2022 Impaired platelet adhesion \u2022 Reduced FVIII activity Rare: acquired cases due to vWF antibodies in connection with autoimmune diseases, lymphoproliferative diseases, or after multiple transfusions (\"von Willebrand syndrome, \" VWS). Defects in the vWF-binding glycoprotein GPIb can mimic von Willebrand's disease (\"Pseudo-VWD\").",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Attention when Caring for Infants"
        },
        {
            "text": "Frequency Definition \u2022 Type 1: mild form, bleeding time \u2191, discrete tendency to bleed, epistaxis, gum bleeding, increased menstruation, bleeding after minor surgery \u2022 Type 2: different characteristics depending on subtype; increased soft tissue bleeding, mucous membrane bleeding, gastrointestinal bleeding, hematuria; bleeding into joints less common than with hemophilia; rarely intracerebral bleeding \u2022 Type 3: most severe form with pronounced bleeding (soft tissue bleeding, bleeding into joints, and petechial type bleeding) \u2022 ATTENTION: in all types life-threatening bleeding may occur up to 14 days after surgery.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Type"
        },
        {
            "text": "\u2022 Medical history (including family history) \u2022 Physical examination including type of bleeding Systemic consumption coagulopathy due to release of coagulation activators, with intracapillary coagulation, microthrombus formation, subsequent ischemic organ damage (kidney, liver, lung) and organ failure. Diffuse tendency to bleed due to collapsed hemostasis with secondary hyperfibrinolysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "Acute DIC is a severe life-threatening disease. Chronic DIC with continuous coagulation may occur in patients with malignant diseases.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History, Physical Examination"
        },
        {
            "text": "\u2022 Infections: sepsis (gram-negative / gram-positive), malaria, rickettsia, chlamydia, mycobacteria, meningococcus (Waterhouse-Friderichsen syndrome: consumption coagulopathy with adrenocortical bleeding), viral infections \u2022 Solid tumors: carcinomas of the lung, pancreas, stomach, colon, prostate, Kasabach-Merritt syndrome (hemangiomas) \u2022 Hematological neoplasia: acute promyelocytic leukemia (FAB M3) \u2022 Obstetric complications: placenta abruptio, amniotic fluid embolism, septic abortion, eclampsia, postpartal hemolytic-uremic syndrome \u2022 Hypoxia and shock: traumatic, hemorrhagic, cardiac, septic \u2022 Hemolysis: transfusion errors, toxins, paroxysmal nocturnal hemoglobinuria \u2022 Operations on organs with a high thrombokinase content (prostate, pancreas, lung), extracorporeal circulation (contact activation of the endogenous coagulation system) \u2022 Trauma: head injury, soft tissue damage, fat embolism \u2022 Others: snake bites, heat stroke (endothelial damage), abdominal aortic aneurysms",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Excessive Release of Activators of the Coagulation Cascade"
        },
        {
            "text": "Excessive thrombin synthesis leads to fibrin formation and subsequent intravascular coagulation with consumption of platelets and clotting factors. Inhibitory mechanisms (e.g., inhibition of FVa and FVIIIa via thrombomodulin-activated protein C) cannot compensate the thrombin formation. . DIC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pathophysiology: Four Phases"
        },
        {
            "text": "Initially (phase I and II), pathological laboratory parameters only. Only with severe consumption coagulopathy (phase III) clinically detectable symptoms:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "J. Heinz"
        },
        {
            "text": "\u2022 Hemorrhagic diathesis with ubiquitous bleeding, 75% of cases: skin / mucous membrane bleeding, hematomas, secondary bleeding after venipuncture / from puncture sites, pulmonary hemorrhage, gastrointestinal bleeding, renal bleeding, hematuria, adrenal bleeding / insufficiency, intracerebral bleeding \u2022 Multiple microthromboses with impaired organ function, 70%: acute renal failure, impaired liver function, acute respiratory insufficiency (ARDS, \"acute respiratory distress syndrome\"), intradermal microvascular thrombosis \u2192 \"purpura fulminans\" (skin bleeding with central necrosis), cerebral small vessel ischemia (coma, epileptic seizures) \u2022 Shock: tachycardia, decrease in blood pressure, edemas, organ failure \u2022 Chronic course: coagulation factor synthesis \u2191, thrombosis \u2191 \u2192 malperfusion of larger blood vessels (embolisms, cerebral ischemia, etc.)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "J. Heinz"
        },
        {
            "text": "\u2022 Case history including risk factors \u2022 Physical examination",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Case History, Physical Examination"
        },
        {
            "text": "I Activation Rapid decrease of platelets, platelet count n / \u2193, antithrombin n / \u2193, FV n / \u2193, FVIII n / \u2193, coagulation products \u2191 (soluble fibrin, prothrombin fragment F1+2, thrombin-antithrombin complex TAT) II Early consumption Platelets \u2193, antithrombin \u2193, Quick \u2193, coagulation factors (fibrinogen, FV) \u2193, PTT \u2191, TAT \u2191, protein C \u2193 III Late consumption Platelets \u2193\u2193 (< 30,000/\u00b5l), antithrombin \u2193\u2193, Quick \u2193\u2193, coagulation factors \u2193\u2193 (fibrinogen, FV, and FVIII), PTT \u2191\u2191, thrombin time \u2191\u2191, fibrinogen degrading products / fibrin monomers +, D-dimers +++, detectable fragmentocytes IV Recovery Decrease in coagulation products (soluble fibrin, prothrombin fragment F1+2, TAT), increase of clotting factors (fibrinogen, FV, FVIII), normalization of global clotting tests n normal, F factor, TAT thrombin-antithrombin complex, PTT partial thromboplastin time",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Phase Description Parameters"
        },
        {
            "text": "\u2022 Basic diagnosis: platelets (platelet decrease often first symptom), antithrombin, D-dimers, fibrinogen, Quick's test, PTT \u2022 Advanced diagnosis: fibrin monomers (soluble fibrin), prothrombin fragments F1+2, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex, factor V, protein C, possibly protein S (in cases of purpura fulminans)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagnostic Key Parameters"
        },
        {
            "text": "Basic screening test Score A score \u2265 5 indicates ongoing DIC; with scores < 5 diagnostics should be repeated every 12-24 h depending on the individual clinical condition.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DIC scoring system of the ISTH (International Society on Thrombosis and Hemostasis)"
        },
        {
            "text": "\u2022 With tumors / infections / pregnancy, the platelet count is often increased (\"reactive thrombocytosis\") \u2192 normal platelet counts may already indicate DIC. \u2022 Fibrinogen is an acute-phase protein \u2192 \"normal\" fibrinogen levels may already be pathologically decreased (e.g., with infections). \u2022 With DIC, frequent monitoring is required to determine the dynamics and course of disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ATTENTION:"
        },
        {
            "text": "\u2022 Primary hyperfibrinolysis: normal platelet count, normal ATIII, no fibrin monomers",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ATTENTION:"
        },
        {
            "text": "Basic therapy \u2022 Antithrombin (AT) replacement if AT level < 70% (initially 1,000 IU, then 500 IU every 6 h), check level (target: 80-100%) \u2022 Heparin: 100-300 IU/kg/day (not with AML type M3 or patients with high bleeding risk), depending on platelet count Organ dysfunction, bleeding \u2022 Fresh frozen plasma (FFP, 10 ml/kg) \u2022 Antithrombin (AT), 500-1000 IU every 6 h \u2022 Fibrinogen replacement with fibrinogen levels of < 100 mg/dl \u2022 Platelet transfusion (target: > 50,000/\u03bcl) \u2022 Red cell transfusion according to hemoglobin level, compensation of acidosis \u2022 Heparin is contraindicated, no intramuscular injections \u2022 Patients should be treated in intensive care unit \u2022 Severe uncontrollable bleeding: administration of activated FVIIa. ATTENTION: potential risk of thromboembolic complications ATTENTION: administration of coagulation factors can increase DIC and should be avoided. For replacement therapy, use fresh frozen plasma (FFP).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Principles of DIC Treatment"
        },
        {
            "text": "\u2022 Severe sepsis: activated protein C (drotrecogin) 24 \u00b5g/kg/h over 96 h \u2192 decreases mortality from 31% to 25%. ATTENTION: with thrombocytopenia higher risk of hemorrhagic complications. Contraindicated after brain hemorrhage, epidural catheter, etc. \u2022 In DIC, avoid fibrinolysis inhibitiors: \u2192 in cases of uncontrollable bleeding: use aprotinin (e.g., 250,000 units in the first half hour, followed by 2 million units/day), platelets, fibrinogen, and PPSB. In cases of life-threatening bleeding or lack of success: administer recombinant FVIIa. \u2022 Fibrinolysis inhibitors (antifibrinolytics, e.g., tranexamic acid) may be indicated with hyperfibrinolytic conditions (prostate carcinoma, AML M3) in phase I of a DIC only. \u2022 Low-dose heparinization is indicated in cases of: purpura fulminans, acral ischemia, venous thrombosis. For phase I, some studies favor low-molecular weight heparin (100-200 units/kg/ day).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Special Cases"
        },
        {
            "text": "\u2022 Clinical monitoring: close monitoring of neurological, cardiovascular, respiratory and renal parameters \u2022 Monitoring of bleeding: tachycardia, hemoglobin decrease, retroperitoneal bleeding (\u2192 sonography), neurology \u2022 Laboratory tests: coagulation parameters, blood count, hepatic and renal function parameters, electrolytes Dd: Dd:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring During Treatment"
        },
        {
            "text": "Th: Th:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring During Treatment"
        },
        {
            "text": ". DIC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring During Treatment"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "platelet aggregation inhibitors (acetyl salicylic acid, ticlopidine, clopidogrel)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "New therapies for ITP",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Andemariam",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bussel",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Curr Opin Hematol",
            "volume": "14",
            "issn": "",
            "pages": "427--458",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy",
            "authors": [],
            "year": 2003,
            "venue": "British Committee for Standards in Hematology (BCSH)",
            "volume": "120",
            "issn": "",
            "pages": "574--96",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "AMG 531, a thrombopoiesis stimulating protein, for chronic ITP",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Bussel",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Kuter",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "George",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "N Engl J Med",
            "volume": "355",
            "issn": "",
            "pages": "1672--81",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Management of adult idiopathic thrombocytopenic purpura",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Cines",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mcmillan",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Annu Rev Med",
            "volume": "56",
            "issn": "",
            "pages": "425--467",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "George",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Woolf",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "E"
                    ],
                    "last": "Raskob",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Ann Med",
            "volume": "30",
            "issn": "",
            "pages": "38--44",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Long-term outcomes in adults with chronic ITP after splenectomy failure",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mcmillan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Durette",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Blood",
            "volume": "104",
            "issn": "",
            "pages": "956--60",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Morbidity and mortality in adults with idiopathic thrombocytopenic purpura",
            "authors": [
                {
                    "first": "Jea",
                    "middle": [],
                    "last": "Portielle",
                    "suffix": ""
                },
                {
                    "first": "Rgj",
                    "middle": [],
                    "last": "Westendorp",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kluin-Nelemans",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Blood",
            "volume": "97",
            "issn": "",
            "pages": "2549--54",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Long-term observation of 208 adults with chronic idiopathic thrombocyto--Argatroban: direct thrombin inhibitor, interacts with the active site of thrombin. Half-live 24 min., monitored by PTT. No dose adjustment in renal failure",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Stasi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Stipa",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Masi",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "\u2022 In cases of existing thrombosis: coumarin overlapping with danaparoid or hirudin. \u2022 Avoid using LMWH",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "How I treat heparin-induced thrombopenia and thrombosis",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Alving",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood",
            "volume": "101",
            "issn": "",
            "pages": "31--38",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Heparin-induced thrombocytopenia",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Arepally",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "L"
                    ],
                    "last": "Ortel",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "N Engl J Med",
            "volume": "355",
            "issn": "",
            "pages": "809--826",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Keeling",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Davidson",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Watson",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Br J Haematol",
            "volume": "133",
            "issn": "",
            "pages": "259--69",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Newman",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "H"
                    ],
                    "last": "Chong",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Blood",
            "volume": "96",
            "issn": "",
            "pages": "182--189",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Delayed-onset heparin-induced thrombocytopenia",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Rice",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "K"
                    ],
                    "last": "Attisha",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Drexler",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Ann Intern Med",
            "volume": "136",
            "issn": "",
            "pages": "210--215",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Cancer-related anemia: pathogenesis, prevalence and treatment",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Birgegard",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Aapro",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bokemeyer",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Oncology",
            "volume": "68",
            "issn": "1",
            "pages": "3--11",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bokemeyer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Aapro",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Courdi",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Eur J Cancer",
            "volume": "40",
            "issn": "",
            "pages": "2201--2217",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Guidelines for the clinical use of red cell transfusion",
            "authors": [],
            "year": 2001,
            "venue": "British Committee for Standards in Hematology (BCSH)",
            "volume": "113",
            "issn": "",
            "pages": "24--31",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "The impact of hemoglobin levels on treatment outcomes in patients with cancer",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Littlewood",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Semin Oncol",
            "volume": "28",
            "issn": "8",
            "pages": "49--53",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Red cells I: inherited anaemias",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Provan",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Weatherall",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Lancet",
            "volume": "355",
            "issn": "",
            "pages": "1169--75",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Red cells II: acquired anemias and polycythaemia",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Provan",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Weatherall",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Lancet",
            "volume": "355",
            "issn": "",
            "pages": "1260--1268",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "ASH/ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Rizzo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Somerfield",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "L"
                    ],
                    "last": "Hagerty",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Blood",
            "volume": "111",
            "issn": "",
            "pages": "x--y",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Modern treatment of thalassaemia intermedia",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Borgna-Pignatti",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Br J Haematol",
            "volume": "138",
            "issn": "",
            "pages": "291--304",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis",
            "authors": [],
            "year": 2004,
            "venue": "Br J Haematol",
            "volume": "126",
            "issn": "",
            "pages": "455--74",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Hereditary elliptocytosis: spectrin and protein 4.1R",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Gallagher",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Semin Hematol",
            "volume": "41",
            "issn": "",
            "pages": "142--64",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Management of cold haemolytic syndrome",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gertz",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Br J Haematol",
            "volume": "138",
            "issn": "",
            "pages": "422--431",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "The complement inhibitor eculizumab in PNH",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hillmen",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "S"
                    ],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Schubert",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "N Engl J Med",
            "volume": "355",
            "issn": "",
            "pages": "1233--1276",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Treatment of autoimmune hemolytic anemia",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Ness",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Semin Hematol",
            "volume": "42",
            "issn": "",
            "pages": "131--137",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Glucose-6-phosphate dehydrogenase deficiency",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mehta",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "J"
                    ],
                    "last": "Mason",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Vulliamy",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Baillieres Best Pract Res Clin Haematol",
            "volume": "13",
            "issn": "",
            "pages": "21--38",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Sickle-cell disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Stuart",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Nagel",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Lancet",
            "volume": "364",
            "issn": "",
            "pages": "1343--60",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Recessively inherited coagulation disorders",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Manucci",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Duga",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Peyvandi",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Blood",
            "volume": "104",
            "issn": "",
            "pages": "1243--52",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Mechanisms of disease: the impact of antithrombotic therapy in cancer patients",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Petralia",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Lemoine",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "K"
                    ],
                    "last": "Kakkar",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nat Clin Pract Oncol",
            "volume": "2",
            "issn": "",
            "pages": "356--63",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Coagulation Disorders \u2022 FFP 10 ml/kg (coagulation factor increase by",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "10--20",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "\u2022 Antithrombin concentrate: 20 IU/kg \u2192 increase by approximately",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "20--40",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Dahlback",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Intern Med",
            "volume": "257",
            "issn": "",
            "pages": "209--232",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Delgado",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Jimenez-Yuste",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Hernandez-Navarro",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Br J Haematol",
            "volume": "121",
            "issn": "",
            "pages": "21--35",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "The antiphospholipid syndrome",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Levine",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "W"
                    ],
                    "last": "Branch",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rauch",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "N Engl J Med",
            "volume": "346",
            "issn": "",
            "pages": "752--63",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Identification of the gene for vitamin K epoxide reductase",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Chang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "Y"
                    ],
                    "last": "Jin",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nature",
            "volume": "427",
            "issn": "",
            "pages": "541--545",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Rituximab in the treatment of acquired factor VIII inhibitors",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wiestner",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "J"
                    ],
                    "last": "Cho",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Asch",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Blood",
            "volume": "100",
            "issn": "",
            "pages": "3426--3434",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Treatment of acquired hemophilia by the Bonn-Malm\u00f6 protocol",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zeitler",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Ulrich-Merzenich",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hess",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Blood",
            "volume": "105",
            "issn": "",
            "pages": "2287--93",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Immune tolerance induction: recombinant vs. human-derived product",
            "authors": [],
            "year": 2001,
            "venue": "Th: Th: Ref: Ref: Web: Web: Berntorp E",
            "volume": "7",
            "issn": "",
            "pages": "109--122",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Haemophilia 2002: emerging risks of treatment",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Evatt",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Farrugia",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Haemophilia",
            "volume": "8",
            "issn": "",
            "pages": "221--230",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Haemophilia A: from mutation analysis to new therapies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Graw",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Brackmann",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Oldenburg",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nat Rev Genet",
            "volume": "6",
            "issn": "",
            "pages": "488--501",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Recombinant activated factor VII in patients at high risk of bleeding",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Kubisz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stasko",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Hematology",
            "volume": "9",
            "issn": "",
            "pages": "317--349",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Dose and response in haemophilia: optimization of factor replacement therapy",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Srivastava",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Br J Haematol",
            "volume": "127",
            "issn": "",
            "pages": "12--25",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Comparing outcomes of different treatment regimens for severe haemophilia",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "M"
                    ],
                    "last": "Van Den Berg",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Fischer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "G"
                    ],
                    "last": "Van Der Bom",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Haemophilia",
            "volume": "9",
            "issn": "",
            "pages": "27--31",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Consensus perspectives on prophylactic therapy for haemophilia: summary statement",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Berntorp",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Astermark",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bj\u00f6rkman",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Haemophilia",
            "volume": "9",
            "issn": "1",
            "pages": "1--4",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Inhibitor development in haemophilia B",
            "authors": [
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Michele",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Br J Haematol",
            "volume": "138",
            "issn": "",
            "pages": "305--320",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Recombinant activated factor VII in patients at high risk of bleeding",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Kubisz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stasko",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Hematology",
            "volume": "9",
            "issn": "",
            "pages": "317--349",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Dose and response in haemophilia: optimization of factor replacement therapy",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Srivastava",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Br J Haematol",
            "volume": "127",
            "issn": "",
            "pages": "12--25",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Stobart",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Iorio",
                    "suffix": ""
                },
                {
                    "first": "Jk ; Cd003429",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "M"
                    ],
                    "last": "Van Den Berg",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Fischer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "G"
                    ],
                    "last": "Van Der Bom",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Cochrane Database Syst Rev",
            "volume": "9",
            "issn": "",
            "pages": "27--31",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Prg: Prg: Px: Px: Ref: Ref: Web: Web",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Ref: Web: Web: In cases of manifest severe DIC: 50-80% mortality Administration of heparin 10",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "0--15",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Efficacy and safety of recombinant human activated protein C for severe sepsis",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "R"
                    ],
                    "last": "Bernard",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Vincent",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "F"
                    ],
                    "last": "Laterre",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "N Engl J Med",
            "volume": "344",
            "issn": "",
            "pages": "699--709",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "The prothrombotic state in cancer: pathogenetic mechanisms",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "De Cicco",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Crit Rev Hematol Oncol",
            "volume": "50",
            "issn": "",
            "pages": "187--96",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Update on the treatment of disseminated intravascular coagulation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Franchini",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Manzato",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Hematology",
            "volume": "9",
            "issn": "",
            "pages": "81--86",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "Disseminated intravascular coagulation: what's new?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Crit Care Clin",
            "volume": "21",
            "issn": "",
            "pages": "449--67",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "DIC 2002: a review of disseminated intravascular coagulation",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Toh",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Dennis",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Hematology",
            "volume": "8",
            "issn": "",
            "pages": "65--71",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "High dose antithrombin III in severe sepsis",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Warren",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Reid",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Singer",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "JAMA",
            "volume": "286",
            "issn": "",
            "pages": "1869--78",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "DIC in acute leukemia: clinical and laboratory features at presentation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Yanada",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Matsushita",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Suzuki",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Eur J Haematol",
            "volume": "77",
            "issn": "",
            "pages": "282--289",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Thrombosis: localized intravascular aggregation of blood components \u2192 thrombus (clot) formation with consecutive vascular occlusion",
            "authors": [],
            "year": null,
            "venue": "Clinical symptoms differ depending on the blood vessels affected: venous or arterial thrombosis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Embolism: migration of detached thrombus (clot) elements in the blood stream with consecutive vascular occlusion. Triggers: thrombotic material, tumor particles or leukemic cell thrombi, sclerotic material, fat droplets, amniotic fluid, air. Thrombophilia: increased risk of occurrence of thromboembolic events",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "Thrombosis incidence: 3 cases/1,000 population/year; location: > 90% in inferior vena cava or leg / pelvic veins; male:female = 1:1; particularly in patients > 50 years of age",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Idiopathic\" deep vein thrombosis or pulmonary embolism in clinically \"healthy\" adults is due to an underlying malignancy in 6-35% of cases Pulmonary embolisms or venous thromboses are found in up to 50% of cancer patients at autopsy Virchow Triad: Major Pathomechanisms of Thrombogenesis \u2022 \u2022 \u2022 Endothelial alterations: vascular sclerosis, inflammation, trauma, etc. Circulation disorders: intravascular stasis, vortex formation",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Endothelial Alterations (esp. with Arterial Thrombosis)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "phlebitis Circulation Disorders \u2022 Immobilization, bed rest \u2022 Intravascular stasis due to vascular constriction or compression: e.g., after extended periods of travel (\"economy class syndrome\"), varicosis, obesity, pregnancy, solid tumors, or lymphomas \u2022 Altered blood flow due to cardiac disorders",
            "authors": [],
            "year": null,
            "venue": "\u2022 Arteriosclerosis \u2022 Vascular puncture, vascular prostheses, trauma \u2022 Vasculitis (arteritis nodosa, thromboangiitis obliterans, etc.)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Hypercoagulability Thrombocytosis E.g., myeloproliferative syndromes (7 Chap. 7.3) Def: Def: ICD-10: ICD-10: Ep: Ep: Pg: Pg: . Thromboembolism and Thrombophilia",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "APC (activated protein C) resistance: most common cause of thrombophilia; in 95% of cases due to factor V mutations \u2192 abnormal APC binding site (mainly point mutations in the factor V gene, G1691A, \"factor V Leiden\") \u2192 insufficient inactivation of factor V by mutated APC. Prevalence: heterozygotic carriers 3-9% of normal population, 20-40% among patients with thrombosis. Relative thrombosis risk in heterozygotic cases approximately 3-to 7-fold, in homozygotic cases 50-to 100-fold increased. Other causes (< 5%) for APC resistance: antiphospholipid antibodies, oral contraceptives, pregnancy. Factor II mutation: prothrombin mutation G20120A, often associated with increased prothrombin levels. Prevalence: heterozygotic carriers 2-4% of normal population; among patients with thrombosis 5-7%. Relative risk of thromboembolisms: 2-to 4-fold increased. Factor VIII increase: 25% of thrombosis patients show persistent FVIII increase of unknown etiology",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "Antithrombin / protein C / protein S defects: rare hereditary disorders; AT deficiency especially is associated with a high risk of thrombosis. DD: hepatic diseases. Hyperhomocysteinemia: hereditary defect of cystathionine \u03b2 synthetase; or acquired due to vitamin B6, B12, or folic acid deficiency. Antiphospholipid syndrome: most common acquired form of thrombophilia; occurs as primary or secondary (as a result of systemic lupus erythematosus SLE, collagenosis, malignancy, medication, infections) subtype",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "\u2212 Rapid onset of the anticoagulation effect; minimal laboratory monitoring required (platelet count during first 3 weeks, antifactor Xa levels in patients with renal failure, cachectic, or overweight patients) hemorrhagic complications, osteoporosis, and heparin",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "000 IU bolus > 70 kg; then continuous intravenous treatment: 30,000 IU/24 h, maximum 50,000 IU/24 h; dosage according to PTT: target PTT > 60-90 s, first PTT test after 6 h, then every 12 h; once stable, it is sufficient to check PTT once daily \u2022 Alternatively, subcutaneous administration: 7,500-10,000 IU s.c. 3 times daily; studies have shown that with identical PTTs, intravenous and subcutaneous administration are equally effective \u2022 Side effects: hemorrhage (in up to 10% of patients), hypersensitivity (urticaria, bronchospasm, fever, even shock), alopecia (rare), vasospasm (rare), osteoporosis (with long-term use), heparin-induced thrombocytopenia",
            "authors": [],
            "year": null,
            "venue": "\u2022 Effect: inhibition of thrombin, factor Xa, IXa, half-life: 60 min \u2022 Intravenous bolus: 5,000 IU i.v. in patients < 70 kg",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "\u2022 Arterial occlusion (extremity arteries, acute myocardial infarction",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "Discontinuation of Heparin Treatment \u2022 Adoption of coumarin: discontinuation of heparin treatment once target INR is reached (usually after 5 days); exception: in cases of extensive thrombosis (calf to pelvis), continue heparin treatment for 10-14 days",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "\u2022 Absence of contraindications and patient compliance provided, LMWH treatment may be possible in an outpatient setting",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Effect Vitamin K antagonism \u2192 inhibition of the hepatic synthesis of coagulation factors F II, VII, IX, X of age, hemorrhagic diathesis, sepsis \u2022 Uncompensated hypertension, liver or renal insufficiency \u2022 Surgery within last 7-10 days, arterial puncture, intramuscular injections \u2022 CNS surgery within the last 3 months, cerebral bleeding, cerebral sclerosis, CSF puncture within the last 10 days \u2022 Pancreatitis, endocarditis lenta, diabetic retinopathy, nephrolithiasis \u2022 Pulmonary / gastrointestinal diseases with high risk of bleeding",
            "authors": [],
            "year": null,
            "venue": "Secondary Prophylaxis: Coumarin (Phenprocoumon)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "P"
                    ],
                    "last": "Baglin",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Cousins",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Keeling",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Br J Haematol",
            "volume": "136",
            "issn": "",
            "pages": "26--35",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "British Committee for Standards in Haematology (BCSH). Guideline. Investigation and management of heritable thrombophilia",
            "authors": [],
            "year": 2001,
            "venue": "Br J Haematol",
            "volume": "114",
            "issn": "",
            "pages": "512--540",
            "other_ids": {}
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "Prophylaxis for thromboembolism in hospitalized medical patients",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Francis",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "N Engl Med",
            "volume": "356",
            "issn": "",
            "pages": "1438--1482",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "The effect of low molecular weight heparin on survival in patients with advanced malignancy",
            "authors": [
                {
                    "first": "Cpw",
                    "middle": [],
                    "last": "Klerk",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Smorenburg",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "M"
                    ],
                    "last": "Otten",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Clin Oncol",
            "volume": "23",
            "issn": "",
            "pages": "2130--2135",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Deep vein thrombosis",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Kyrle",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Eichinger",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Lancet",
            "volume": "365",
            "issn": "",
            "pages": "1163--74",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism",
            "authors": [
                {
                    "first": "Ayy",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "R"
                    ],
                    "last": "Rickles",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Julian",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Clin Oncol",
            "volume": "23",
            "issn": "",
            "pages": "2123--2132",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "Deep venous thrombosis",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Lopez",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Kearon",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Hematology (ASH Educ Program)",
            "volume": "",
            "issn": "",
            "pages": "439--56",
            "other_ids": {}
        },
        "BIBREF90": {
            "ref_id": "b90",
            "title": "ASCO Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "H"
                    ],
                    "last": "Lyman",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Khorana",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Falanga",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Clin Oncol",
            "volume": "25",
            "issn": "",
            "pages": "5490--505",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "Severe aplastic anemia (SAA or VSAA) \u2022 Patient at risk by complications arising from cytopenia (recurrent infections, hemorrhage, hemosiderosis) \u2022 Prevention of alloimmunization and subsequent transfusion refractoriness Treatment of aplastic anemia MRD matched related donor (HLA-identical family bone marrow or stem cell donor)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Th: Th: Th:",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Iron deficiency anemia (iron \u2193, ferritin \u2193, transferrin-binding capacity \u2191) \u2022 Thalassemia (MCV \u2193\u2193, iron, ferritin, and transferrin-binding capacity normal) \u2022 Megaloblastic anemias (vitamin B12 / folinic acid) \u2022 Hemolytic anemia (bilirubin, LDH, haptoglobin, Coombs' test) Treatment of underlying disease Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J 2004;5:373-80 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-33 Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(2 suppl 8):49-53 Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999;70:7-12 Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14-23",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "mg daily p.o. for 4 months. Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med 2001;110:99-105 Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57-67 Provan D, Weatherall D. Red cells II: acquired anaemias and polycythaemia. Lancet 2000;355:1260-8 Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997;337:1441-8 Wickramashinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol 1999;36:3-18 Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol 1999;36:35-46",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": ". Pathophysiology of renal anemia. Clin Nephrol 2000;53(1 suppl):S2-8 Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 2000;20:320-9 MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375-81 Ritz E, Schwenger V. The optimal target hemoglobin. Semin Nephrol 2000;20:382-6 Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;15(suppl 3):23-8",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "NOTE: Treatment-induced reversible hematopoietic insufficiency following chemo-or radiotherapy is not designated as aplastic anemia.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Neonatal isoimmune neutropenia: transplacental passage of maternal antineutrophil antibodies \u2022 Complement activation: hemodialysis, cardiopulmonary bypass, T-\u03b3 diseaseInfections: Increased Margination / Consumption (Pseudoneutropenia)\u2022 Bacteria: typhus, paratyphus, brucellosis, tuberculosis, tularemia \u2022 Viruses: yellow fever, sandfly fever, infectious hepatitis, measles, influenza, chickenpox, German measles, Colorado tick fever, dengue fever, HIV, EBV \u2022 Rickettsia: rickettsial pox, Rocky Mountain spotted fever \u2022 Protozoa: malaria, kala-azar, recurrent fever \u2022 Fungi: histoplasmaOther Causes\u2022 Bone marrow infiltration: leukemia (especially hairy cell leukemia), lymphomas, solid tumors \u2022 Malnutrition: vitamin B12 / folic acid deficiency, alcoholism \u2022 T-cell-associated neutropenia (T-\u03b3 disease), myelodysplasia (MDS) \u2022 DIDMOAD syndrome: diabetes insipidus + diabetes mellitus + optic nerve atrophy + deafness \u2022 Metabolic disorders: hepatic cirrhosis, ketoacidosis, Gaucher's disease \u2022 Sepsis, hypothermia, acute anaphylaxis \u2022 Initially usually asymptomatic \u2022 General symptoms: fatigue, decreased performance, anorexia, infectionsMedical History, Physical Examination\u2022 Medical history: drug treatment, family history, infections, menstrual complaints \u2022 Physical examination: with lymph node status, liver / spleen, signs of infection, mucositisLaboratory Tests\u2022 Blood count with differential, reticulocytes \u2022 Routine laboratory tests including vitamin B12 and folic acid, total protein, protein electrophoresis, urinary protein (paraprotein diagnosis), copper \u2022 Immunology: immunoglobulin assay, immunoelectrophoresis, Coombs' test, ANA, anti-DNA, rheumatoid factor, granulocyte antibodies Infection monitoring: blood, fecal, and urine cultures, throat swab, viral serology (including HIV) \u2022 Cytogenetics \u2022 Ham's test, sugar water test (exclusion of PNH)",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious and idiosyncratic neutropenias. Semin Hematol 2002;39:113-20 Welte G, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006;43:189-95",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Disorders of Thrombopoiesis\u2022 Infections (most common cause): e.g., CMV, EBV, HIV, mycoplasma, bacterial infection, parasites (malaria), sepsis (early symptom) \u2022 Hematopoietic (bone marrow) deficiency: aplastic anemia, primary myelofibrosis \u2022 Bone marrow infiltration: leukemia, lymphomas, solid tumors \u2022 Abnormal megakaryocytic maturation: myelodysplasia, folic acid / vitamin B12 deficiency \u2022 Drug-induced / toxic myelosuppression: cytostatics, thiazides, alcohol, estrogens, thiamazole,",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": ".2) \u2022 Evans' syndrome: autoimmune hemolytic anemia and thrombocytopeniaHemorrhage\u2022 Petechial type of hemorrhage with small pinpoint lesions on skin / mucous membranes, occasionally epistaxis, menorrhagia \u2022 In rare cases: hematoma / bruising / diffuse hemorrhage Exclusion of pseudothrombocytopenia by means of platelet count in citrated blood \u2022 Viral serology (HIV included) \u2022 With suspected vasculitis / SLE \u2192 immunology: antinuclear antibodies (ANA), rheumatoid factor \u2022 With suspected HUS / TTP: screening for abnormal VWF multimers or VWF protease anti-",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "\u2022 In cases of drug-induced thrombocytopenia: avoid causative agent \u2022 Treatment of malignancies \u2022 Treatment of immunological disordersSupportive Treatment\u2022 Prevention of menstrual bleeding (e.g., lynestrenol) \u2022 Avoid platelet aggregation inhibitors (acetyl salicylic acid) \u2022 Platelet transfusion at signs of bleeding / acute risk of hemorrhage (ATTENTION: HUS /",
            "latex": null,
            "type": "table"
        },
        "TABREF11": {
            "text": "With adequate treatment (plasmapheresis, dialysis, supportive treatment), good prognosis: \u2022 Response rate: 80-90%, mortality 5-20% \u2022 Relapse rate: 15-20% \u2022 In 15-20% of cases, chronic disease-related effects: renal dysfunction, residual cerebral disorders",
            "latex": null,
            "type": "table"
        },
        "TABREF12": {
            "text": "Nomenclature of Red Cell ChangesSize (Indices: Erythrocyte Diameter, MCV)\u2022 Macrocytosis: erythrocyte diameter \u2191, MCV \u2191 \u2022 Microcytosis: erythrocyte diameter \u2193, MCV \u2193 \u2022 Anisocytosis: pronounced variations in size of RBC Shape \u2022 Poikilocytosis: different RBC shapes in blood smear \u2022 Elliptocytes: oval RBC \u2022 Spherocytes: spherical cells \u2022 Target cells: target-like appearance \u2022 Acanthocytes: irregularly spiculated cells, \"spur cells\" \u2022 Schistocytes: RBC fragments, fragmentocytes \u2022 Dacryocytes: drop-shaped cells, \"teardrop\" RBC \u2022 Drepanocytes: sickle cells (bipolar spiculated cells) \u2022 Hypochromic: RBC staining \u2193, MCH \u2193 \u2022 Hyperchromic: RBC staining \u2191, MCH \u2191 \u2022 Polychromatic: reddish-blue-gray staining Symptoms of Anemia \u2022 Pallor of skin and mucous membranes, nail beds, conjunctivae \u2022 Weakness, tiredness, reduced performance \u2022 Lack of concentration, headache, vertigo \u2022 Dyspnea, tachycardia, palpitations (esp. with acute anemia) History, Physical Examination \u2022 Risk factors, esp. infections, drugs, bleeding (menstruation history), nutritional habits \u2022 Physical examination including skin, mucous membranes, lymph node status, spleen / liver findings, heart (tachycardia, particularly systolic murmur), rectal examination with fecal blood test, gynecological examination Laboratory Tests \u2022 Hematology: blood count, with MCV, MCH, reticulocytes, differential blood count, blood smear \u2022 Clinical chemistry: routine tests with bilirubin, renal function parameters, total protein, protein electrophoresis, iron status (iron, ferritin, transferrin-binding capacity), parameters of hemolysis (bilirubin, LDH, haptoglobin), CRP, BSG, vitamin B12 / folinic acid \u2022 Coombs' test (if hemolytic anemia is suspected) \u2022 Virus serology (including parvovirus B19) \u2022 Blood group \u2022 Erythropoietin level (if renal anemia is suspected)Bone marrow aspiration / biopsy, with iron stain (if stem cell/bone marrow disorder is suspected)",
            "latex": null,
            "type": "table"
        },
        "TABREF13": {
            "text": "D.P. Berger, R. Engelhardt, T. HeinzCauses of Iron Deficiency\u2022 Poor iron uptake: infants, small children, vegetarians, alcoholics, nutritional disorders. \u2022 Recommended daily uptake: men 12 mg, women 15 mg, pregnancy 30 mg. \u2022 Decreased resorption: postoperative (gastrectomy), malassimilation \u2022 Increased need: growth, pregnancy, lactation period, during treatment of vitamin B12 deficiency \u2022 Blood loss: urogenital / gastrointestinal bleeding, cystitis, angiodysplasia, esophagitis, hemorrhoids \u2022 Infection / parasites (worldwide most frequent cause of iron deficiency: hookworm infection)",
            "latex": null,
            "type": "table"
        },
        "TABREF14": {
            "text": "\u2022 Pallor of skin and mucous membranes, nail beds, conjunctivae \u2022 Weakness, tiredness, reduced performance \u2022 Lack of concentration, headache \u2022 Exertional dyspnea, tachycardia, palpitations (DD: cardiac failure)",
            "latex": null,
            "type": "table"
        },
        "TABREF15": {
            "text": "\u2022 History: infections, drugs, exposition to hazardous substances, bleeding \u2022 Physical examination: skin, mucous membranes, lymph node status, spleen / liver, heart (tachycardia, systolic murmur), rectal examination with fecal blood test Clinical chemistry: renal function parameters, iron status (iron \u2193, ferritin \u2191, transferrin-binding capacity \u2191), ESR \u2191, fibrinogen \u2191, CRP \u2191, haptoglobin \u2191 (acute-phase protein), possibly erythropoietin level \u2022 Blood group (if red cell substitution necessary)",
            "latex": null,
            "type": "table"
        },
        "TABREF18": {
            "text": "Hemolysis Parameters\u2022 LDH \u2191, HBDH \u2191, serum iron \u2191 \u2022 Indirect bilirubin \u2191, urinary urobilinogen \u2191 \u2022 Haptoglobin \u2193 \u2022 Hemoglobin \u2193, hematocrit \u2193, erythrocyte count \u2193 \u2022 Reticulocytes \u2191 (with chronic hemolysis) \u2022 Erythrocyte survival time \u2193",
            "latex": null,
            "type": "table"
        },
        "TABREF19": {
            "text": "In cases of severe anemia / hemolytic crises (10-15% of cases): splenectomy (not in patients under 5 years of age and preceded by splenic scintigraphy to exclude accessory spleens); consider subtotal splenectomy. Vaccination against S. pneumoniae, N. meningitidis and H. influenza mandatory.",
            "latex": null,
            "type": "table"
        },
        "TABREF20": {
            "text": "\u2192 Defects in the erythrocytic pentose phosphate pathway \u2192 NADPH synthesis \u2193 \u2192 decreased glutathione (GSH) \u2192 Lysis of erythrocytes due to oxidative stress, hemolytic crises",
            "latex": null,
            "type": "table"
        },
        "TABREF24": {
            "text": "Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin.",
            "latex": null,
            "type": "table"
        },
        "TABREF27": {
            "text": "dimers \u2191, fibrinogen \u2193 as a sign of hyperfibrinolysis \u2022 Treatment of the underlying disease \u2022 In case of thrombocytopenia and hemorrhage: administration of platelet concentrates \u2022 In case of paraprotein-associated hemorrhage (Waldenstr\u00f6m's macroglobulinemia or multiple myeloma): administration of DDAVP, in case of severe hyperviscosity: apheresis treatment \u2022 Hyperfibrinolysis: antifibrinolytics (e.g., aprotinin)",
            "latex": null,
            "type": "table"
        },
        "TABREF28": {
            "text": "Drug-induced: penicillin, ampicillin, interferon-\u03b1 \u2022 Others: post partum, skin diseases, sarcoidosis, amyloidosis, GVHD Spontaneous bleeding with large hematomas, mucous membrane hemorrhages, vaginal bleeding, in severe cases uncontrollable bleeding after minor injuries; high mortality of up to 25%\u2022 aPTT \u2191, factor VIII \u2193 \u2022 Determination of inhibitor levels according to the Bethesda methodAcute Hemorrhage\u2022 Administration of recombinant factor VIIa \u2022 In cases of low titer inhibitors (< 5 B.U.): administration of high-dose factor VIII \u2022 In severe cases additional administration of activated prothrombin complex concentrate, immunoadsorption therapyCausal Treatment\u2022 Immunosuppressive treatment: steroids (prednisone 1 mg/kg daily for at least 4 weeks), possibly in combination with cyclophosphamide (2 mg/kg daily) \u2022 Alternatively: i.v. immunoglobulins 1 g/kg daily for 2 days, cyclosporine, anti-CD20 antibody (rituximab) \u2022 In cases of high titer inhibitors > 5 B.U. or severe bleeding: immunoadsorptionAcquired von Willebrand's SyndromeOccurrence of von Willebrand factor inhibitors in conjunction with: \u2022 Malignancies: lymphomas, leukemias, myeloproliferative diseases, solid tumors \u2022 Cardiovascular diseases \u2022 Autoimmune diseases, drugs \u2022 Autoantibodies against von Willebrand factor \u2022 Binding of von Willebrand factor to the surface of malignant cells \u2022 Proteolysis of von Willebrand factor (e.g., with acute promyelocytic leukemia 7 Chap. 7.1.2) \u2022 High shear stress \u2192 destruction of vWF multimers (e.g., in cases of aortic stenosis) \u2022 Impaired synthesis Skin / mucous membrane hemorrhage, postoperative bleeding See congenital von Willebrand's syndrome(7 Chap. 6.5.4)    \u2022 Treatment of the underlying disease \u2022 Replacement therapy with von Willebrand concentrate, inhibitor elimination",
            "latex": null,
            "type": "table"
        },
        "TABREF29": {
            "text": "Increased tendency to bleed (manifestation during infancy and early childhood)\u2022 Extensive bleeding, hematomas \u2022 Soft tissue bleeding, bleeding into joints (hemarthrosis) \u2022 Gastrointestinal bleeding, hematuria Medical History, Physical Examination \u2022 Medical history: including family history \u2022 Physical examination: including type of bleeding, complications Laboratory Tests \u2022 Coagulation parameters: factor VIII \u2193\u2193, aPTT \u2191, Quick's test normal (extrinsic system), normal bleeding time (verified by platelet function test) \u2022 Genetic diagnosis: RFLP (analysis of the restriction fragment length polymorphism); most common genetic defect: intron 22 inversion \u2022 Von Willebrand's disease \u2022 Other coagulation factor deficiencies \u2022 Acquired factor VIII antibodies (7 Chap. 6.5.1) \u2022 Arthropathy \u2192 joint destruction, arthrosis, stiffening \u2022 Retroperitoneal bleeding, psoas hemorrhage, cerebral bleeding (rare) \u2022 Hepatitis / HIV infection due to transfusion and administration of FVIII products (especially before 1984). HIV patients on protease inhibitor treatment: bleeding risk \u2191 \u2022 Pseudotumor formation / liquefaction of tissue at the hemorrhage site \u2192 surgical excision Def: Def: ICD-10: ICD-10: O. Schmah, J. Heinz Detailed recommendations see guidelines of the International Society for Thrombosis and Hemostasis. The following types of treatment can be distinguished: \u2022 Treatment on demand (spontaneous / traumatic bleeding) \u2022 Continuous prophylactic treatment (esp. children and teenagers) \u2022 Prophylactic treatment (before surgery, physical stress, etc.)",
            "latex": null,
            "type": "table"
        },
        "TABREF30": {
            "text": "). Coagulation factors are applied i.v. as a slow bolus injection or via continuous infusion (2-4 IU/ kg/h) with reduced factor content. Required Amount: Dose (IU) = Desired Factor Increase (%) \u00d7 0.5 \u00d7 Body Weight (kg) Rule of Thumb: Administration of Factor VIII 1 IU/kg \u2192 Plasma FVIII \u2191 by 1% Dosage guidelines for FVIII Therapeutic factor VIII activity in plasma b Or until wound healing is completeMonitoring of FVIII ReplacementaPTT monitoring is not sufficient, specific measurement of plasma factor VIII should be performed.\u2022 Determine FVIII level 30-60 min after bolus was administered = confirmation of increase;when biological half-life is reached, and prior to administration of the next dose \u2022 15-35% of patients develop antibodies against infused factor VIII \u2192 alloantibodies may form within the first 50-100 days of exposure, and may lead to treatment resistance \u2192 monitoring via FVII inhibitor assayPatients with Factor VIII Antibodies\u2022 Hemorrhage and low antibody titer (Bethesda titer < 5): increase dose and frequency of FVIII products, close monitoring; use of porcine FVIII may be considered (no cross-reaction) \u2022 Hemorrhage and high antibody titer (Bethesda titer > 5): give recombinant factor VIIa 90 \u00b5g/ kg body weight (= 4.5 KIU/kg body weight) every 2-4 h or Factor Eight Bypassing Activity Th: Th:",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "Hereditary coagulopathy due to deficiency or inactivity of coagulation factor IX (FIX, Christmas factor, antihemophilic globulin B, AHG-B).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "annex"
        },
        {
            "text": "Rare hereditary coagulopathy, incidence 1 case/25-30,000 men/year. Women are heterozygotic carriers of the gene.\u2022 Factor IX coding gene is located on the X chromosome \u2192 mainly men are affected, X-linked recessive inheritance; hereditary forms (80% of cases) and spontaneous mutations (20%) \u2022 Hepatic synthesis, 55 kDa protein, vitamin K-dependent, half-life 24 h ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D67"
        },
        {
            "text": "\u2022 Mild bleeding: vasopressin analog desmopressin (DDAVP), nasal spray or intravenously, e.g., every 12-24 h 0.3 \u00b5g/kg body weight i.v. in 100 ml saline 0.9% over 30 min \u2192 release of vWF in endothelium, increase of the vWF level by factor 3-5. Response within 30-60 min in > 80% of patients; duration of effect 8-10 h. Since not all patients respond, conduct provocation test prior to treatment; treatment must be interrupted after 3-5 days due to depletion of endogenous vWF stores. \u2022 With menstruation, single doses of DDAVP prior to menstruation are usually sufficient; supportive estrogen therapy with subtype 1. \u2022 Severe bleeding: similar strategy to type 2B, 2N, and 3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bleeding in VWD Subtypes 1, 2A, or 2M"
        },
        {
            "text": "\u2022 Administration of high-vWF plasma products (e.g., 20-70 U/kg 2-4 times daily or 3-5 U/kg/ h per infusor) until ristocetin cofactor activity > 60% for at least 72 h. ATTENTION: Recombinant FVIII products contain no vWF and are ineffective in von Willebrand's disease \u2192 use special high-vWF plasma or FVIII products. \u2022 Platelet concentrates \u2022 If surgery is planned: vWF antigen as well as ristocetin cofactor activity should be 60%, pre-as well as postoperatively. \u2022 ATTENTION: With subtype 2B, DDAVP did not demonstrate a clear benefit (risk of thrombocytopenia). With subtype III, it is ineffective.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bleeding in VWD Subtypes 2B, 2N, and 3"
        },
        {
            "text": "\u2022 Monitoring of vWF antigen, FVIII function (FVIII:C), ristocetin cofactor (RiCof) according to disease subtype.Th: Th:. Von Willebrand's Disease\u2022 Development of vWF alloantibodies in 10-15% of cases, risk of anaphylactic reactions with repeated exposure. With neutralizing antibodies and bleeding complications factor VIIa may be given.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of Substitution"
        },
        {
            "text": "\u2022 If DDAVP has proven to be effective, give 30 min prior to surgery \u2022 High risk of hemorrhage (e.g., tonsillectomy): raise vWF antigen and ristocetin cofactor activity up to 60%; administer high-vWF FVIII concentrate \u2022 Intraoperative use of fibrin glue and fibrinolysis inhibitors (e.g., tranexamic acid mouthwash with dental surgery)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adjuvant Treatment / Preparation for Surgery"
        },
        {
            "text": "\u2022 During pregnancy, hormone-induced increase in vWF and FVIII:C \u2192 with subtype 1 and 2 no further treatment required \u2022 Peripartum: keep vWF antigen and Ristocetin cofactor activity above 50%; with cesarean section, aim for 100% pre-and postoperatively ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "During Pregnancy"
        },
        {
            "text": "\u2022 Vessel wall defects: endothelial alterations due to intravascular catheters / lines, antineoplastic treatment, direct invasion of tumor tissue; cytokine-mediated activation of the endothelium \u2192 enhanced expression of tissue factor / adhesion molecules / PAI and decreased endothelial thrombomodulin expression \u2192 thrombophilic surface \u2022 Changes in blood flow: immobilization, tumor-related vascular compression, stasis, hyperviscosity \u2022 Changes in coagulation system: fibrinogen \u2191, factor V \u2191, FVIII \u2191, von Willebrand factor \u2191, FXII \u2191, AT \u2193 \u2022 Release of procoagulating substances (\"cancer coagulants, \" e.g.,tissue factor = TF, FX activators) with activation of the extrinsic system via factor VII or direct FX activation; high levels of TF in promyelocytes of acute leukemia type FAB M3 \u2022 Decrease in coagulation inhibitors (antithrombin, protein C and S) due to chemotherapy (asparaginase) ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reasons for Increased Thrombogenesis in Patients with Malignancies"
        },
        {
            "text": "\u2022 Swelling of the arm, hyperthermia, livid discoloration, tightness \u2022 Pain in forearm, upper arm and/or shoulder, fever veins, mesenteric veins); thromboembolic event despite effective anticoagulation; thrombosis during pregnancy and tendency to miscarriage and stillbirth \u2212 Analysis of: fibrinogen, antithrombin, protein C, protein S, prothrombin (FII), FVIII, APC resistance, factor II mutation, antiphospholipid antibodies (lupus anticoagulants, anticardiolipin antibodies), plasminogen deficiency \u2212 Extended diagnostics: homocysteine, methyltetrahydrofolate reductase (MTHFR) mutation G77T, FIX, and FXII \u2212 In most cases, repeated tests are required. With suspected thrombophilia, patients should be referred to specialized hematology centers. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Phlebothrombosis of the Arm (Paget-von Schroetter Syndrome)"
        },
        {
            "text": "\u2022 Venous thrombi \u2192 pulmonary embolism (in > 95% of cases due to phlebothrombosis, approximately 50% of patients with phlebothrombosis develop pulmonary embolism) \u2022 Arterial / cardiac thrombi \u2192 cerebral malperfusion, renal infarction, extremities",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Thrombosis-related Complications"
        },
        {
            "text": "\u2022 Post-thrombotic syndrome (after 10-15 years, in 40-60% of conventionally treated patients) \u2022 Chronic leg ulcer (in 10% of patients)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Long-term Sequelae of Lower Extremity DVT"
        },
        {
            "text": "\u2022 Effect: factor Xa inhibition, half-life: 100-180 min \u2022 Dosage: enoxaparin 1 mg/kg twice daily s.c., dalteparin 100 IU/kg twice daily, or tinzaparin 175 IU/kg once daily \u2022 Advantages of treatment with LMWH compared to UFH:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Low Molecular Weight Heparin (LMWH)"
        },
        {
            "text": "According to INR (\"international normalized ratio\"). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dosage"
        },
        {
            "text": "In normal weight patients (\u2248 70 kg), the following rule of thumb applies: current Quick value divided by 10 is the number of coumarin tablets to be given in the first 4 days. On day 1, give 3 tablets, on days 2 and 3 give 2 (or 1) tablets (slow initiation to reduce the risk of coumarin necrosis). The INR should be checked on day 4. The result determines the dosage of subsequent treatment. Heparin treatment may be discontinued once the target INR has been reached (usually after 5-6 days).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment Initiation"
        },
        {
            "text": "The duration of anticoagulation treatment has to be determined individually for each patient, based on thrombosis type, location, risk factors and comorbidities. Guideline: ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Duration of Treatment: Depending on Thrombosis Type"
        },
        {
            "text": "Patients with contraindications against coumarin may receive low molecular weight heparin as secondary prophylaxis on a long-term basis. Half the therapeutic LMWH dose is usually recommended (comparable to an INR of 2-3); start after 10-14 days of \"full dose\" therapeutic LMWH treatment. Cancer patients in particular benefit from treatment with low molecular weight heparin.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Prophylaxis Alternative"
        },
        {
            "text": "Due to frequent occurrence of hemorrhagic complications (10-15%), increased mortality (1-2%) and limited long-term benefit (no reduction in occurrence of post-thrombotic syndrome), fibrinolysis now only plays a secondary role. An indication for treatment with fibronolytics (e.g., streptokinase, urokinase) may exist in young patients with extensive fresh thrombosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Thrombolytic Therapy (Fibrinolysis Treatment)"
        },
        {
            "text": "Surgical thrombectomy allows immediate perfusion of the blood vessel. However, endothelial injury and incomplete thrombus removal often lead to rapid reformation of thrombi. Indications: \u2022 Phlegmasia cerulea dolens \u2022 Fresh isolated descending pelvic vein thrombosis (not older than 1-2 days) \u2022 Acute arterial occlusion",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Surgical Thrombectomy"
        },
        {
            "text": "Placement of a filter in the V. cava reduces the risk of severe pulmonary embolism in patients with recurrent thromboses. Indications are:\u2022 Recurrent pulmonary embolism despite effective anticoagulation \u2022 Contraindication against anticoagulants",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cava Filter"
        },
        {
            "text": "\u2022 Immobilization: studies did not confirm a role for immobilization in the prevention of pulmonary embolisms. \u2022 In patients with severe pain or edema: elevation and immobilization of the leg for a limited number of days. \u2022 Compression therapy: compression dressings with bandages or compression stockings; contraindicated with peripheral arterial occlusive disease and phlegmasia cerulea dolens. Compression stockings should be worn for at least 2 years as secondary prophylaxis after DVT of the lower extremity. In most cases, calf compression stockings on the affected leg are sufficient.\u2022 Anticoagulants \u2022 Platelet aggregation inhibitors, acetylsalicylic acid 100 mg daily p.o. (protective effect in particular with arterial occlusion and coronary heart disease) \u2022 Elimination of risk factors (see above), early postoperative mobilization, physiotherapy, compression stockings",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supportive Treatment"
        }
    ]
}